annual report 2012 - shpa.org.au · PDF fileThe Society of Hospital Pharmacists of Australia...

The Society of Hospital Pharmacists of Australia ABN 54 004 553 806 annual report 2012 page 1

annual report 2012

The Society of Hospital Pharmacists of Australia



shpa annual report 2012

shpa contact details Federal SecretariatLocation: Suite 3, 65 Oxford Street, CollingwoodMail: PO Box 1774, CollingwoodVictoria 3066, Australia

Telephone 61 3 9486 0177Facsimile 61 3 9486 0311Email [email protected] Website www.shpa.org.au

PublisherThe Society of Hospital Pharmacists of Australia



contentsintroduction to shpa 6membership report 7 shpa federal secretariat 7shpa federal councillors 8from the president 9farewell to Yvonne Allinson 10education and professional 11 developmentadvocacy 12workforce 13membership 13specialty practice 13rural network 17national pharmacy technician network 17research and development 18publications 18jppr 19shpa branches 19from the treasurer 24directors’ report 25financial report 2011/12 27


introduction to shpaSHPA was established in 1941 following the pioneering efforts of 25 public hospital pharmacists in Victoria. From 1947 to 1964 other branches were developed. The inaugural meeting of the SHPA Federal Council and the first SHPA national conference were held in Adelaide in 1961.

SHPA is now the professional body for more than 3000 pharmacists, pharmacy technicians and associates practising in all parts of the Australian health system. It is the only pharmacy organisation in Australia whose core member base is pharmacists practising in hospitals.

SHPA helps to optimise health outcomes for individuals and the community by improving medicines management. SHPA is committed to facilitating the safe and effective use of medicines by supporting pharmacists, technicians, pharmacy students, pharmacy service delivery and all other health professionals involved in medicines management.

The diversity of SHPA’s members’ practice settings reflects contemporary pharmacy practice. While SHPA member services particularly support pharmacists and other health professionals practising in hospitals, clinical pharmacy services, which were once confined to the hospital environment, are now delivered in a wide array of practice settings. Therefore, SHPA membership is valuable and relevant to pharmacists and others who provide services in private hospitals, medicines management programs, community pharmacy, academia, research, industry, government, quality use of medicines programs, and more.

Safe and effective medication use is the core business of pharmacists, especially in hospitals.

During 2011 SHPA celebrated two milestones – 70 years since its inception and 50 years as a national organisation. SHPA marked these achievements during the gala dinner at Medicines Management 2011 – the 37th SHPA National Conference in Hobart, November 2011. Some of SHPA’s longest serving members joined the President, Sue Kirsa to cut the commemorative cake.

the shpa vision:Excellence in medicines management through leading edge pharmacy practice and research

the shpa mission: ■ Supporting the continuing professional development of our members ■ Having strong membership within hospitals and all other quality use of medicines settings ■ Partnering with key medicines stakeholders ■ Advocating for the safe and effective use of medicines across the continuum of care

the shpa values: ■ Teamwork ■ Integrity ■ Recognition ■ Respect ■ Innovation

Helen Matthews (Vic.), Bill Thomson (Vic.), Peter Custance (WA), Ian Larmour (Vic.), Kay Hynes (Vic.), Sue Kirsa (SHPA President), Anne Leversha (Vic.), Mel Davis (NSW), Penny Thornton (NSW).


membership report to 30 June 2012

honorary inactive life member overseas student associate technician total %

ACT 0 6 1 57 0 5 1 2 72 2NSW 1 35 14 570 0 133 2 12 767 25Qld 0 26 9 580 0 32 2 9 658 22SA/NT 1 16 5 260 0 51 0 7 340 11Tas. 0 5 0 72 0 16 0 3 96 3Vic. 3 28 25 716 0 51 2 21 846 28WA 1 10 5 184 0 39 0 7 246 8Not in Aust. 2 0 0 9 9 3 0 0 23 1TOTAL 8 126 59 2448 9 330 7 61 3048 100

membership by type:

shpa federal secretariatstaff members (listed below alphabetically as at 30 June 2012) play a critical role in providing member services and supporting SHPA activities from the national headquarters

membership by branch:

Della AbsalomAssistant to Federal Secretariat (part time)

Yvonne AllinsonSenior Adviser (part time)

Anna BorgAdministrative Coordinator

Nicki BurridgePublications Coordinator (part time)

Marlene CartlidgeAssistant to Managing Editor, JPPR (part time)

Natalie CollardPublications Pharmacist

Cassie FerstererProfessional Development Coordinator (part time)

Vikki GillAssistant to Federal Secretariat (part time)

Stacey HallAssistant to Federal Secretariat

Natalie JenkinsProfessional Development Coordinator (on maternity leave)

Benafsha KhariwalaManaging Editor, JPPR (part time)

Vishal Naidu Assistant Accountant / Finance Officer

Suzanne NewmanCommunications Coordinator (part time)

Karen O’LearyPolicy and Projects Manager (part time)

Sally RidgersSponsorship and Conference Manager (part time)

Michael TsuiBusiness Manager (part time)

Sarah TurnbullAssistant to Federal Secretariat

Sally WilsonResearch into Practice Pharmacist (part time)


On behalf of all members, SHPA thanks and gratefully recognises the significant contributions made by Natalie Bula (ACT), Sharon Goldsworthy (SA & NT) and Rebekah Moles (NSW) during their terms on Council which ended in November 2011.

Without the dedication and efforts of volunteers who serve on Federal Council, SHPA would not be able to realise its vision and expand the range of services provided to members.

shpa federal councillorsas at 30 June 2012

shpa executive councillors

shpa councillors

Suzanne W KirsaSuzanne W KirsaFederal PresidentCouncillor from 2009 (Vic.)Director of PharmacyPeter MacCallum Cancer Centre

Anthony D Hall Federal TreasurerCouncillor from 2004 (Qld)Senior Lecturer, School of PharmacyGriffith UniversityGold Coast Campus

Catherine HughesCouncillor from 2011 (SA & NT)Director Country Pharmacy ServicesSA Pharmacy, SA Health

Helen A Lovitt-RaisonCouncillor from 2007 (WA)Senior PharmacistFremantle Hospital and Health Service

thanks to former councillors

Karen I Kaye 4th Executive MemberCouncillor from 2007 (NSW)Executive ManagerPrograms and Services, NPS, Better choices, Better health (NPS MedicineWise)

Amber RobertsFederal Vice-President Councillor from 2005 (Tas.)Statewide Medication CoordinatorMedication Strategy and Reform, Dept.Health and Human Services Tas.

Alexandra (Sasha) A BennettCouncillor from 2011 (NSW)Executive OfficerNSW Therapeutic Advisory Group

Ian CoombesCouncillor from 2009 (Qld)Director of PharmacyThe Royal Brisbane and Women’s Hospital

Emily DiproseCouncillor from 2011 (ACT)Deputy Director of PharmacyCalvary Health Care ACT

Megan F MiddletonCouncillor from February 2008 (Vic.)Lead Project PharmacisteCare@Eastern, Eastern Health


from the presidentThis past year has been one of major change for SHPA with the departure of Yvonne Allinson as the CEO and the search for a new CEO.

Yvonne’s contribution to SHPA cannot be overestimated; her achievements for SHPA, the pharmacy profession and the healthcare sector during her 12-year tenure have been remarkable. Yvonne’s drive, perseverance and tireless efforts in advocating for the pharmacy profession and the patients they serve as well as the strong member and patient-centred culture she has fostered within the organisation will enable SHPA to flourish.

SHPA appointed Helen Dowling as the new CEO, to commence in July 2012. Helen comes to SHPA with a long history of active involvement in SHPA at many levels. Her achievements and commitment to pharmacy practice were recognised in 2005 when she was awarded the GlaxoSmithKline Medal of Merit. SHPA is fortunate to be able to appoint a person of Helen’s calibre to the CEO position. Her experience, leadership, vision and commitment make her a perfect fit for this position and I believe that SHPA will prosper during her tenure. I would like to acknowledge the work of the SHPA’s wonderful staff who have kept the secretariat running very smoothly over the period between Yvonne’s departure and Helen’s arrival. SHPA is very fortunate to have such wonderfully dedicated staff looking after the interests of our members.

This year has seen many enhancements to the benefits of SHPA membership. Responding to member feedback CE on CD is now available on DVD so members receive more presentations and a pause function; shpaclinCAT is now fully functioning with 46 trained clinCAT evaluators across the country; the shpaeCPD Moodle website is now offering many CPD activities, instructional videos, ebooks and more; the COSP in Clinical Pharmacy has published a series of quick guides based on the SHPA Standards of Practice for Clinical Pharmacy; SHPA has three new publications – the 5th edition of the Australian Injectable Drugs Handbook (AIDH), the Australian Don’t Rush to Crush Handbook: Therapeutic options for people unable to swallow solid oral medicines, and the Australian Medicines Information Training Workbook. The availability of the Moodle platform has enabled SHPA to provide to members the Medicines Information Training Workbook as an online learning module and a learning module An Introduction to the Australian Don’t Rush to Crush Handbook based on the Australian Don’t Rush to Crush Handbook. Due to increased demand, much work was put into expanding the clinical seminar program to include three new topics and scheduling additional seminars for popular topics. SHPA is also keeping in touch with members and prospective members using social media; SHPA now has about 800 Facebook and 270 Twitter followers. Medicines Management 2011, themed Make Your Move was held in Hobart and was a great success, with nearly 900 delegates. The conference organising committee should be congratulated on hosting this outstanding event.

With the help of an unrestricted grant from Celgene, SHPA appointed a Research into Practice Pharmacist. The purpose of this role is to distill all the evidence that highlights the ways that pharmacists can make a difference and improve medicines management into a format that is clear to all. Three Medicines in Focus Fact Sheets have been developed and published, outlining the evidence for the need for pharmacists in emergency departments, pre-surgery assessment clinics and medical assessment and planning units. These fact sheets have been well received, with very positive feedback from pharmacy managers and members.

SHPA places great importance on taking opportunities to influence policies and decisions that affect members and pharmacy practice. SHPA takes part in reference groups, steering committees and submits written responses to consultation papers. Some of the issues that SHPA has spoken up on include: Medicare Locals Guidelines, prescribing competencies, advanced pharmacy practice framework, personally controlled electronic health record, activity-based funding for hospitals, drug shortages, hospital initiated home medicines reviews, supply of PBS medicines to remote area Aboriginal health services, rural health workforce, the implementation of the 5th Community Pharmacy Agreement professional programs, accreditation of pharmacy schools, accreditation of CPD activities for pharmacists, medication management in residential aged care facilities and quality and safety in health care. Karen O’Leary at the Federal Secretariat should be acknowledged for her efforts in preparing multiple submissions for SHPA, especially in the absence of a CEO for an extended period.

During 2011, SHPA devoted much effort to the Pharmacist Coalition for Health Reform (PCHR) to enable national pharmacist groups (APESMA, NAPSA, PSA and SHPA) to provide a united voice. All organisations agreed that pharmacists were underutilised and governments and decision makers needed to be aware of the skills that pharmacists had and the ways they could contribute. The theme Pharmacists: the best kept secret in healthcare was well received and the group gained much early traction and publicity on some contentious issues. However, it was disappointing that the Coalition disbanded within a year; the different governance structures of the member organisatons meant that action in a timely manner was difficult to achieve.

SHPA’s achievements and improvements in member benefits can only happen with the efforts of the range of volunteers who are the lifeblood of SHPA – i.e. those who serve on Federal Council, committees of specialty practice, branch committees, special interest groups, Research and Development Grants Advisory Committee, conference and branch symposium organising committees and the many other contributions of time and effort that members make when they feel they can make a difference.

In closing, it gives me great pleasure to announce the recipients of SHPA’s major awards for 2012, which will be presented at the Medicines Management 2012 conference in Canberra, November 2012. Congratulations to:

Rohan Elliott, recipient of the GlaxoSmithKline Medal of Merit; and Jason Roberts, recipient of the Australian Clinical Pharmacy Award.

SUE KIRSAFederal President


farewell to Yvonne AllinsonThe 23rd of December 2011 heralded the end of an era for SHPA. It was on this day that Yvonne Allinson indicated to the President of SHPA that she intended to accept an offer to work with the NPS. Yvonne, CEO of SHPA for 12 years, oversaw a period of great change and growth for our organisation. Many of SHPA’s significant achievements over these years can be directly attributed to Yvonne’s vision and leadership. As current and former Presidents of SHPA during her tenure, we would like to chronicle some of those achievements, and pay tribute to Yvonne’s significant contributions.

The year 2000 was challenging for SHPA. We posted a significant financial deficit and the late Pam Nieman, our incumbent CEO, had resigned for personal reasons. The Council of the day, led by Helen Dowling, set out to find a new CEO. Yvonne, whose name was recommended, was at the time working with the Victorian Department of Human Services as the Project Manager for Change Management, Education and Training initiatives for Information, IT and Telecommunications Strategy for public hospitals. Yvonne took some convincing to leave the public sector and commenced on 24 July 2000.

Yvonne came with an impressive track record as a business woman, educator, clinical pharmacist, editor of the Australian Injectable Drugs Handbook and Director of Pharmacy Services. The Council recognised in Yvonne a hospital pharmacist who would understand the objectives of SHPA and a leader who was well connected with the profession, government and departmental officials in local and federal jurisdictions.

Yvonne set out with a number of goals to improve SHPA’s financial position, increase membership and to raise our profile with government and among other health professions. In her unique style, Yvonne achieved those goals, and leaves an organisation that is vastly different but undoubtedly altered for the better.

Yvonne guided Council to take the leap from tenant to property owner, and to move the secretariat from its rented premises in Albert Street, South Melbourne to a small unit in Raglan Street. The secretariat of the day consisted of an Office Manager and the CEO, so these premises seemed like they would last some time.

Around this time, the profession was going through a difficult and challenging period. There was a shortage of pharmacists and times were tight in hospitals, signalling that we could no longer rely on the goodwill of volunteer members to provide administrative and professional services for the organisation. In order to support members to contribute their intellectual input into our specialty activities and CE programs it became necessary for the secretariat to grow and for salaried staff to take on the administrative tasks. Over this period, Council made some major decisions, e.g. changes to the fellowship program, adoption of the Commission for Certification in Geriatric Pharmacy as SHPA’s pathway to achieving accreditation to conduct home medicine reviews and reinventing the delivery of CE to members via new technologies. Guided by an astute CEO, SHPA managed to maintain a clear and distinct identity among the pharmacy organisations.

Another major decision taken by Council, in response to the introduction of the GST and Branches struggling with a changing fiscal environment, was to bring all the financial reporting activities in-house to the secretariat. This was designed to lighten the accounting burden on the Branch Committees. Considerable time and effort was devoted by Yvonne and the Council in consultation with the Branches to ensure the change was equitable. Branches could continue to provide membership services, without the paperwork involved in the day-to-day management of their finances.

In the ensuing years, the Clinical Conferences were introduced – a concept that would merge with the biennial federal conference into the annual Medicines Management Conference. The Council, under Yvonne’s guidance and commonsense approach, endorsed the notion that an annual small and less extravagant conference would allow members to come together more often to celebrate their achievements, learn and network. A 2-day program was devised, with a pre-conference ‘COSP’ day and a post-conference leadership day. Yvonne guided successive conference organising committees through a streamlined conference format. Pharmaceutical industry sponsorship and relationships were also centralised to bring all negotiations in-house and provide a single point of contact.

As the secretariat was poised to grow with the recruitment of pharmacist project officers and then permanent staff members supporting the COSP, publications, membership benefits and the advocacy work, it became apparent that the small unit in Raglan Street was no longer sufficient. Yvonne once again led the Council in finding premises with potential for rental income and room for future expansion. Council agreed that this would be a secure investment, and with strategic engagement of senior and influential members of the day, Council agreed to sell the Raglan Street premises and invest in the upcoming suburb of Collingwood.

Yvonne’s diligent application of sound business principles has laid the foundation that puts SHPA in a solid financial position, allowing it to focus on membership services, advocating for a strong and active profession, and better healthcare for patients. SHPA has played a significant role in important health reforms over the last decade – introduction of the PBS into public hospitals, mandating CPD for registered pharmacists, introduction and rollout of the Australian Pharmaceutical Advisory Council guidelines, and the recognition of a role for SHPA on the Programs Reference Group of the 5th Community Pharmacy Agreement. Her persistence and influence, both inside and outside the profession often resulted in SHPA being invited to sit with the decision makers.

Yvonne has guided successive Councils in making difficult decisions and balancing multiple interests and demands to achieve the overall good of a national organisation. She has steered SHPA in achieving its strategic mission and staying true to its values and ideals and accountable to members. Yvonne’s open style, marketing flair and commitment to better internal communication with Branches and members helped to consolidate SHPA into a truly national organisation.

Her accolades include the development and rollout of the SHPA ClinCAT program, a new publication Don’t Rush to Crush, a burgeoning advanced practice recognition program, a vibrant and popular CE program, a growing membership base and a sound financial position.

In 2012, SHPA is an organisation well respected for its integrity and knowledge, but we are poised on the precipice once again. For the profession to grow into its full potential as integral to the healthcare team, fully participating and influencing patient outcomes through safe and effective use of medicines, we need strong leaders who are prepared to stand up and fight for patients and the profession.

Yvonne’s legacy has been to position us to take that next giant leap in the evolution of the profession. With courage and strong leadership, we will reach those goals. SHPA owes Yvonne an enormous debt of gratitude which should be repaid by seizing the opportunity and seeing this journey through to the conclusion for our patients and for the generations of pharmacists who come after us.

We wish Yvonne all the very best for the next part of her journey. We have all enjoyed the opportunity to work, learn and develop during our time as Federal President with Yvonne. We know she will continue to strive for the best for patients and the profession in her new role at the NPS. Finally, we offer her our sincere thanks for her dedication, commitment, passion and leadership as the CEO of SHPA.

Helen Dowling, Helen Matthews, Vaughn Eaton, Neil Keen, Sue Kirsa


education and professional developmentdeveloping and maintaining the skills and competence of pharmacistsCPD has continued to grow for SHPA in 2011/2012. The Pharmacy Board of Australia’s mandatory CPD requirements have provided further impetus to members to undertake CPD activities, and this is reflected in a high level of participation by members in all aspects of the shpacpd program.

The range and delivery of activities offered by SHPA as part of its educational program continues to be overseen by SHPA’s Education Reference Group comprised of Councillor Ian Coombes (Chair), Supporting Councillor Sasha Bennett, Chris Alderman, Chris Doecke, Jeff Hughes, Neil Cottrell and Rohan Elliott who have met twice in the 2011/2012 financial year.

CPD Online

In 2011/2012, over 94 sets of self-assessment questions were developed and made available in the CPD Online section of the website. Over 5000 sets of self-assessment questions were submitted online during this period. Self-assessment questions are developed for JPPR articles, CE on Disk presentations, AJP clinical articles (submitted by SHPA to the AJP every two months), SHPA case studies, SHPA branch events and SHPA seminars.

Moodle

Several activities from CPD online have been transferred onto the Moodle platform (now known as eCPD), including self-assessment questions for CE on Disk, JPPR and case studies. The Moodle site has improved features which include the ability to watch CE on Disk presentations online via computer or phone and immediate access to feedback. The latest additions to eCPD include An introduction on Don’t Rush to Crush and Australian Medicines Information Training Workbook, two of SHPA’s newest publications. There are also video recordings of several presentations from the Medicines Management Conference 2011. An online discussion group has been created within Moodle for shpaclinCAT trained evaluators. The plan for 2012/2013 is to eventually move all shpaCPD onto the Moodle platform. CE on Disk

Formerly known as CE on CD, CE on Disk was launched in 2011/2012. CE on Disk, in DVD format, builds on the established SHPA member benefit that allows members to view SHPA branch continuing education lectures in their own time, by allowing a pause function and the ability to include more presentations. Disks 13 (CD) and 14 (DVD) were released during 2011/12 providing members with a choice of 41 presentations to view at their computer at their preferred time. Eighteen of these presentations had associated self-assessment questions that were posted on the SHPA website. The packaging of the Disk was also improved with a streamlined, durable soft plastic cover.

shpaclinCAT

2011/12 saw the national rollout of shpaclinCAT, SHPA’s national clinical competency assessment tool. Five evaluator training seminars were run in Melbourne and Sydney, as well as conversion workshops for GLF-trained evaluators in Sydney and Brisbane. Feedback on the seminars has been extremely positive. As at 30 June 2012, there were 130 pharmacists who had attended training and 46 trained evaluators. SHPA has plans to run more conversion workshops in Queensland, as well as training seminars in Tasmania, South Australia, Western Australia and the Northern Territory in 2012/13.

SHPA gratefully acknowledges the shpaclinCAT Reference Group members: Neil Keen (WA), Miriam Lawrence (ACT), Rohan Elliott (Vic.), Duncan McKenzie (Tas.), Susan Parry (Vic.), Deb Rowett (SA), Andy Lo (Qld), Anne Leversha (Rural Australia), Kirstie Galbraith (Monash University) and Peter Barclay (NSW).

SHPA Seminars in 2011/12

Thirteen seminars were convened by SHPA during 2011/12 and again proved very popular with a combined total of more than 650 registrants. SHPA gratefully acknowledges PDL for their support and sponsorship of the clinical seminars.

Many thanks to the teams who conducted or supported these seminars:

Aged Care Seminar, Sydney, July 2011: Dr Lisa Pont, Stefan Kowalski, Joyce CooperEvidence Based Practice Seminar, Adelaide, August 2011: Prof Jeff Hughes, A/Prof Neil Cottrell, Karen Bailey, Cassie HewtonHaematology/Oncology (Intermediate) Seminar, Melbourne, August 2011: Julie Wilkes, Tien Yen Yee, Melanie Poorun, Geeta Sandhu, Dan Mellor, Jim Siderov, Tracy Shields, John Coutsouvelis, Sandy ScholesshpaclinCAT Evaluator Training Seminar, Sydney, August 2011: Karen Bettenay, Lynda Cardiff, Lauren Cortis, Miriam Lawrence, Jessica Parker, Dr Eleanor Flynn, Debra Rowett, Yvonne Allinson, Natalie JenkinsshpaclinCAT Evaluator Training Seminar, Sydney, September 2011: Karen Bettenay, Lynda Cardiff, Lauren Cortis, Miriam Lawrence, Jessica Parker, Dr Eleanor Flynn, Debra Rowett, Yvonne Allinson, Natalie JenkinsIntroductory Seminar: Clinical Pharmacy Practice, Melbourne, February 2012: Dr Lisa Pont, Dr Michael Barras, Anne Leversha, Sally Marotti, Sharon Goldsworthy, Dr Rebekah MolesshpaclinCAT Evaluator Training Seminar, Melbourne, February 2012: Kirstie Galbraith, Jessica Parker, Olivia Rofe, Dr Eleanor Flynn, Yvonne Allinson, Cassie FerstererLaboratory Tests Seminar, Sydney, March 2012: Prof Jeff Hughes , Bhavini Patel, A/Prof Neil Cottrell


shpaclinCAT Evaluator Training Seminar, Sydney, March 2012: Kirstie Galbraith, Cathy Martin, Miriam Lawrence, Dr Eleanor Flynn, Yvonne Allinson, Cassie FerstererSeminar in Oncology-Introductory, Darwin, April 2012: Julie Wilkes, Melanie Poorun, Scott McGregor, Geoffrey Grima, Gail Rowan, Alison Buete, Michael MaloneyshpaclinCAT Evaluator Training Seminar, Melbourne, April 2012: Kirstie Galbraith, Jessica Parker, Olivia Rofe, Sonia Thomas, Yvonne Allinson, Cassie FerstererCritical Care Seminar, Sydney, May 2012: Robyn Ingram, Tara Crews, Lyn Choo, Belinda Badman, Alastair Bovell, Julie Varghese, Annie EganIntroductory Seminar: Clinical Pharmacy Practice, Gold Coast, June 2012: Dr Lisa Pont, Dr Michael Barras, Sharon Goldsworthy, Sally Marotti

Branch Symposiums

Seven branch symposiums and a director of pharmacy meeting were held by SHPA branches in 2011/12. Major topics covered included antibiotics, poisoning and toxicology, gastroenterology, professional communication, neurology, and transplantation. Two symposiums offered sessions for both pharmacists and technicians and two offered self-assessment questions uploaded onto the SHPA website.

Medicines Management 2011, the 37th SHPA National Conference MM2011 was held in Hobart, November 2011. With a theme of Make Your Move the conference attracted close to 900 delegates, 80 contributed papers and 200 posters. For the first time at the SHPA Conference delegates were able to use a Smartphone app. The app contained the entire conference handbook, program and abstracts. Delegates used the app to plan their day by selecting the presentations they wished to see and this information was added to their conference calendar. Delegates could use the app to Tweet or take notes during presentations which could later be retrieved by emaill.

Many thanks go to the hardworking MM2011 Conference Organising Committee (pictured below) chaired by Amber Roberts and Tom Simpson.

advocacyincreasing the understanding of the pharmacist’s role in improving health outcomes

SHPA values highly its role in influencing policies and decisions that affect members, pharmacy practice and health care. To this end, SHPA invests considerable resources in offering opinions and expertise by having representatives on reference groups and committees and at face-to-face meetings and submitting written responses to consultation papers.

During 2011/12, SHPA has contributed to deliberations on these topics: Medicare Locals, prescribing competencies, advanced pharmacy practice framework, personally controlled electronic health record, activity-based funding for hospitals, drug shortages, hospital initiated home medicines reviews, supply of PBS medicines to remote area Aboriginal health services, rural health workforce, the implementation of the 5th Community Pharmacy Agreement professional programs, accreditation of pharmacy schools, accreditation of CPD activities for pharmacists, medication management in residential aged care facilities and quality and safety in health care.

SHPA was a driving force behind the Pharmacists Coalition for Health Reform (PCHR) through which SHPA worked collaboratively with the other member organisations to inform policy makers and the general public about the roles that pharmacists can have and the difference they can make. Although the PCHR disbanded in May 2012, SHPA is committed to the aims of the PCHR and will continue down that path.

Standing: Leanne Chalmers, Sharon Gordon-Croal, Amber Roberts, Camille Boland, Julie Beechy, Amy McKenzie, Sally Ridgers (SHPA Sponsorship and Conference Manager). Front: Tom Simpson, Duncan McKenzie, Tricia

Hopkins (Conference Logistics). Not pictured: Catherine Drake, Becky Walsh, Cameron Randall.


workforceWhile the workforce situation has improved in recent years with the increase in pharmacy graduates, the larger number of pharmacists has not helped resolve some continuing workforce challenges. Hospitals in rural and remote Australia continue to have more difficulty in attracting pharmacists, and pharmacists with specific skills and experience continue to be hard to find.

To help bridge the deficit of pharmacists with significant experience, SHPA continues its commitment to developing the skills of pharmacists who work in clinical areas by providing clinical seminars and shpaclinCAT – SHPA’s clinical competency assessment tool. shpaclinCAT will help younger pharmacists accelerate the development of their clinical pharmacy skills in hospital practice. SHPA also provides tools to support the pharmacy workforce such as the Clinical Pharmacy Quick Guides and Medicines in Focus Fact Sheets and SHPA’s series of practice standards.

membershipSHPA’s priority is to provide services to members that are of value and relevance. SHPA has again strived to increase and enhance the benefits of SHPA membership. These are some examples of the improvements to SHPA member benefits during 2011/12:

CE on Disk – previously provided on compact disk it is now presented on a DVD. Being on a DVD enables SHPA to include more presentations on each disk – so there is more choice, and the presentations are now in the form of a video that can be paused – so it is more convenient. SHPA has expanded its range of publications to include the Australian Medicines Information Training Workbook and the Australian Don’t Rush to Crush Handbook: Therapeutic options for people unable to swallow solid oral medicines. SHPA continues to seek opportunities to provide more CPD in convenient formats and has increased the amount of CPD available online. Implementing the Moodle platform for the eCPD website has made it easier to provide existing online CPD and to convert SHPA publications into e-learning modules – such as the Australian Medicines Information Training Workbook and An Introduction to Don’t Rush to Crush. SHPA assists members to find relevant CPD by raising awareness of non-SHPA CPD activities via the website and SHPA Bulletin. SHPA helps members by distilling large amounts of information into user-friendly formats – such as the Medicines in Focus Fact Sheets, Activity Based Funding Quick Guides and the Clinical Pharmacy Quick Guides. SHPA has committed resources and support to expand the number of Committees in Specialty Practice, recognising the growth of areas in which pharmacists specialise. SHPA is committed to using technology to enhance member services. SHPA has created a range of videos assist members.

specialty practiceThe Specialty Practice Reference Group reviews the operations and performance of Committees of Specialty Practice (COSPs), oversees the development and maintenance of SHPA practice standards, oversees production of statements by COSPs, encourages the development of a pool of expertise that is available to comment on issues of relevance to hospital pharmacy, encourages and supports the development of specialist educational initiatives by the COSPs, provides advice to Federal Council on formation of or disbanding of COSPs and coordinates (and rotates) the annual pre-conference workshops between COSPs. The development and maintenance of practice standards is integral to the achievement of the SHPA vision of ‘excellence in medicines management through leading-edge pharmacy practice and research.’

SHPA now has 15 active COSPs, including these three new COSPs established during 2011/12: cardiology, palliative care, and pharmacist liaison services.

Specialty Practice Reference Group: Councillor Helen Lovitt (Chair), Supporting Councillor Catherine Hughes, chairs of all COSPs and SHPA CEO and staff Nicki Burridge and Anna Borg.

The standards currently under review and or preparation by the COSPs include: Standards of practice for clinical pharmacy, Standards of practice for the provision of clinical oncology pharmacy services, Standards of practice for the safe handling of cytotoxic drugs in pharmacy departments, Standards of practice for the provision of medicines information services, Standards of practice for drug use evaluation in Australian hospitals and Standards of practice for pharmacists’ role in medication safety and the quality use of medicines. The Standards for the practice of psychiatric pharmacy have been reviewed, adopted by Federal Council and published as the Standards of practice for mental health pharmacy.

Standards of practice are published in SHPA’s Journal of Pharmacy Practice and Research and are also available on the SHPA website.

The SHPA COSP in Clinical Pharmacy has developed six Quick Guides relating to clinical pharmacy services. Each guide provides a one-page summary of the topic, based on the SHPA Standards of practice for clinical pharmacy. The Quick Guides are available on the SHPA website.


The guides are: Assessment of current medication management Clinical review and therapeutic drug monitoring Documenting clinical activities Facilitating discharge and transfer Medication reconciliation Prioritising day-to-day workload.

SHPA sincerely appreciates the contribution of the following COSP members (current as at 30 June 2012) to core SHPA activities, and recognises the achievements of the COSPs during 2011/12.

Clinical Pharmacy

Members: George Taylor (Chair, Tas.), Amber Roberts (convenor), Camille Boland (Tas.), Duncan McKenzie (Tas.), Sally Marotti (SA), Sharon Gordon-Croal (Tas.), Chris Archer (Tas.), Amy McKenzie (Tas.), Nicki Burridge (SHPA), Karen O’Leary (SHPA), Natalie Collard (SHPA), Michael Dooley (Vic.), Jay Fitch (Tas.), Olimpia Nigro (part year, SA), Suzette Seaton (Tas.), Peter Fowler (Tas.), Anne Leversha (SHPA Rural Adviser), Cameron Randall (Tas.).

Outcomes for 2011/12: the COSP in Clinical Pharmacy met six times by teleconference during the year.

The major focus of the COSP has been the review and upgrade of the SHPA Standards of practice for clinical pharmacy. The COSP is formatting the guidelines in a novel way using individual chapters to describe key activities and has published Quick Guides of these activities as appendixes.

The Quick Guides have been published on the SHPA website and are available for use, including on mobile devices.

COSP members continue to work on upgrading of recommended staffing levels for clinical pharmacy service provision which have also been published on SHPA website in advance of completion of guideline review.

Cancer Services

Members: Julie Wilkes (Chair, Vic.), Sue Kirsa (convenor), Michael Cain (WA), Tandy-Sue Copeland (WA), Scott McGregor (WA), Philip Roberts (WA), Melanie Poorun (WA). Ex-officio: Tien Yen Yee (WA), Debbie Bajrovic (WA), Nikki Briegel (WA).

Outcomes for 2011/12: During 2011/12 the Cancer Services COSP: successfully organised and evaluated the fourth Introductory Seminar on Oncology Pharmacy which was held in Darwin, April 2012, including achieving accreditation for Group 2 CPD credits; successfully organised the second Intermediate Clinical Oncology/Haematology Seminar, which was held in Sydney, July 2012, including achieving accreditation for Group 2 CPD credits; developed, used and assessed an app for increasing participant involvement in workshops at the Intermediate Seminar; developed and organised SHPA Pre-Conference Study Day prior to the Medicines Management 2012 Conference in Canberra. Co-ordination with Clinical Oncological Society of Australia’s Cancer Pharmacists Group achieved.

Critical Care

Members: Robyn Ingram (Chair, Vic.), Anthony Hall (convenor), Dennis Leung (NSW), Dianne Milne (SA), Steven Fowler (NT), Niann “Ren” Lau (Qld), Annette Egan (NZ), Dr Julie McMorrow (WA), Belinda Badman (Qld), Bianca Levkovich (Vic.), Jason Roberts (Qld), Lynn Choo (NSW), Stephanie Brumby (Vic.).

Outcomes for 2011/12: the COSP in Critical Care met three times by teleconference during the year. The major activity during this year was the Critical Care Seminar which was held in Melbourne in July 2011, with attention also given to planning two upcoming events: a breakfast session at Medicines Management 2012, the 38th SHPA National Conference in November 2012, and an Intermediate/Advanced Critical Care Seminar to be held in Brisbane in 2013.

The COSP is also working on developing an advanced level framework for ICU pharmacists and facilitating research forums and opportunities for collaborative research for critical care pharmacists.

The COSP’s objective of recruiting more members was successful with the recruitment of Lynn Choo and Stephanie Brumby.

Educational Visiting

Members: Debra Rowett (Chair, SA), Karen Kaye (Convenor), Judy Burrows (Qld), Joy Gailer (SA), Gwen Higgins (NSW), Margaret Jordan (NSW), Karen Luetsch (Qld), Frank May (SA), Jenny Pink (SA), Lisa Pulver (Qld), Cathy Prest (Tas.), Sharon Goldsworthy (SA).

Outcomes for 2011/12: Work has continued with respect to the development of standards of practice for academic detailing services with emphasis on general level and advanced level using the Advanced Pharmacy Practice Framework currently being developed by the Advanced Pharmacy Practice Framework Steering Committee (APPFSC). Once the APPFSC framework is finalised the COSP will more actively pursue work that relates to the competencies, training and assessment. Limited engagement has occurred with other COSPs and this will be a priority in the next year to identify opportunities for collaboration and to increase awareness of this evidence-based approach to facilitate the translation of evidence into policy and practice.


Emergency Medicine

Members: Susan Welch (Chair, NSW), Ian Coombes (convenor), Simone Taylor (Vic.), Linda Graudins (Vic.), Christina Roman (Vic.), Andrew Harding (Vic.), Claire Fitzgerald (NSW), Dona Buchan (NSW), Elizabeth Donegan (Qld), Elizabeth Doran (Qld), Leonie Abbott (Vic.), Melanie Morrow (NT), Sarah Heward (WA), Daniel Guidone (Vic.). There are 149 pharmacists on the email contact list.

Outcomes for 2011/12: during 2011/12 the COSP: held a half-day meeting at MM2011 in Hobart and a teleconference early in 2012; continued the email discussion forum during 2011/12 and received requests from new EM pharmacists to join. Work has started on hosting the email discussion group on the SHPA Moodle website; has been collecting business cases for emergency medicine pharmacist positions; Elizabeth Doran has been working on a standard business case for the COSP to be able to distribute when such requests are made; initiated a multi-centred research project to investigate “Accuracy of medication histories documented on General Practitioner letters for patients presenting to the Emergency Department” which is being compiled for publication; ensured that the information on the SHPA website relating to EM, i.e. EM pharmacy publication and presentation lists and EM seminar information, was current and has been liaising with SHPA Research and Development Grants Advisory Committee to setup and offer an emergency medicine pharmacist grant; contributed to the development of an advanced level competency framework for emergency medicine pharmacists; and has connections with the following groups via COSP members’ participation in these groups; Australian Commission on Safety and Quality in Health Care: Medication Continuity Expert Advisory Group (Susan Welch); NICS Emergency Care Pain Management Initiative steering committee (Simone Taylor); Victorian Department of health Emergency Care Innovation and Improvement Network (Simone Taylor); DrugScan emergency medicine articles for JPPR (Leonie Abbott).

Infectious Diseases

Members: David Kong (Vic., Chair), Catherine Hughes (convenor), Vaughn Eaton (SA), Carol Smith (SA), Matthew Rawlins (WA), Russell Levy (NSW), Evette Buono (NSW), Jason Roberts (Qld), Sharmila Khumra (Vic.), Sean Unwin (Qld), Karlee Johnston (ACT), Duncan McKenzie (Tas.), Verna Wallroth (Tas.), Breigh Ridley (WA), plus about 170 members in the email discussion group.

Outcomes for 2011/12: the committee met about four times this year and members of working parties met every few months.

During 2011/12, the COSP in Infectious Diseases: co-organised the Pharmacy Workshop at the 2012 Australian Society for Antimicrobial’s Annual Scientific Conference in Brisbane, which attracted about 100 pharmacists and clinicians; planned for the Pharmacy Workshop at the 2013 Australian Society for Antimicrobial’s Annual Scientific Conference in Sydney; was represented by David Kong on the Australian Commission for Quality and Safety’s Antimicrobial Stewardship Committee; was involved in work to develop an advanced level framework for infectious diseases pharmacists; committee members participated as guest speakers at selected conferences (e.g. the Feb 2012 ASA Annual Scientific Conference etc.) and local meetings, including teaching undergraduate and postgraduate pharmacy students; successfully completed the development of a two-day Infectious Diseases seminar for pharmacists viz. ‘Introduction to Infectious Diseases Clinical Seminar’ to be held in August 2012; committee members have been involved in developing and teaching into the Infectious Diseases module offered by Monash University and its NAPE partners. The module “Infectious Diseases Pharmacotherapy” continues to be offered to interested pharmacists in 2012. It remains the first of its kind in Australian setting; increased the membership of the COSP email discussion group from about 150 to about 170; strengthened existing relationship with Australian Society for Antimicrobials (ASA) with David Kong continuing as an Executive Member of the ASA; promoted roles of pharmacists in antimicrobial stewardship program through individual COSP members’ activities on SHPA Branch committees, JPPR, Clinical Excellence Commission, NSW TAG DUE group, and the like; continued to actively be involved in educating pharmacists on matters related to Infectious Diseases. We have been working with pharmacists in Victoria to establish a state-based Infectious Diseases Pharmacy group to further strengthen the roles of pharmacy in infectious diseases and support activities of the COSP. Work is in progress to establish a support network for infectious diseases pharmacists in NSW. Our views on the ‘role of pharmacy services’ in infectious diseases continues to be endorsed by the Australian Commission on Quality and Safety in Health Care.

Investigational Drugs

Members: Carol Rice, (Chair, Vic.), Helen Lovitt (convenor), Kay Hynes (Vic.), Jill Davis, (Vic.), Helen Kopp (Vic.), Claire Vosk (Vic.), Eugenie Hong (Vic.), Julie Long (Vic.), Anne Mak (Vic.), Michael Ching (Vic.), Mei Ho (Vic.), Lai Mee Lam (Vic.), Paula Lee (Vic.), Diana Rainbird (Vic.).Corresponding members: Peter Slobodian (SA), Polly Pui (WA), Brenda Shum (WA), Jasminka Sarunac (NSW), Kelvin Robertson (Qld).


Outcomes for 2011/12: the COSP liaised with Therapeutic Goods Administration and Association of Regulatory & Clinical Scientists (ARCS) (COSP members are associate members of ARCS), and with the Medications Management Advisory Group (MMAG).

The web-based Clinical Trials Starter Kit that has been on the SHPA website since November 2009 has been added to with more standard operating procedures and a schedule of fees being added.

A workshop involving lectures by COSP members and interactive workshops is in final planning phase for a one-day seminar in October 2012.

A successful pre-conference seminar was conducted at MM2011 in Hobart, with four invited speakers for an audience of approx. 30 attendees

A number of email discussions have occurred around issues brought up by members or other clinical trial pharmacists who have joined the email list.

Manufacturing

Members: Jane Gillard (Chair, NSW), Karen Kaye (convenor), Nicki Burridge (SHPA), Mel Davis (NSW), Graham Cook (Qld), Siobahn Andrews (Vic.), Andrew Sluggett (SA), Jackie Abercrombie (Vic.), Declan Gibney (NSW).

Outcomes for 2011/12: COSP members have communicated by email and are working towards an easy to use, quality assurance audit tool for hospital manufacturing units as identified by the most recent standards. This simple tool will be able to identify areas for improvement and ensure high standards are maintained.

Medication Safety

Members: Rosemary Burke (Chair, NSW), Anthony Hall (convenor), Angela Wai (NSW), Anne McGrath (Vic.), Bhavini Patel (NT), Chris Doecke (SA), Daniel Lalor (NSW), Elaine Lum (Qld), Elizabeth Anderson (NSW), Linda Graudins (Vic.), Helen Leach (Vic.), Helen Lovitt (WA), Ian Coombes (Qld), Naomi Burgess (SA), Ish Patel (Qld), Jennifer Macdonald (NSW), Julie Stokes (Qld), Toni Howell (Vic.), Penny Thornton (NSW), Diane Reeves (NSW), Rachel Worthington (NSW), Melita Van De Vreede (Vic.).

Outcomes for 2011/12: the COSP in Medication Safety met three times by teleconference and twice in face-to-face meetings. Activities this year included: continuing to provide Medication Safety Briefs for JPPR; planning for Medication Safety Seminar at Medicines Management 2012, the 38th SHPA National Conference; preparing a draft Standards of Practice for Medication Safety and planning for the Medication Safety Toolkit.

Medicines Information

Members: Julie Lord (Chair, Vic.), Graeme Vernon (Secretary, Acting Chair from 29 March 2012, Vic.), Megan Middleton (convenor), Elizabeth Anderson (NSW), Gedal Basman (Vic.), Glen Bayer (Tas.), Cheng Choo (Vic.), Morna Falkland (ACT), Louise Grannell (Vic.), Judith Longworth (NSW), Christine Plover (Vic.), Leone Snowden (NSW), Helen Trenerry (Qld), Rodney Whyte (Vic.), Ruth Wilton (SA).

Outcomes for 2011/12: the COSP in Medicines Information conducted four teleconferences during 2011/12. A major activity this year was the pre-conference meeting in Hobart, November 2011. There were 27 registrants, three non-COSP invited speakers and four COSP members presenting or chairing sessions. The main themes were pharmacogenomics and medicines information skills. The COSP will convene a pre-conference meeting in Canberra on 1 November 2012 titled ‘Chemistry and the clinician: compatibility and stability issues with parenteral drugs’ – work is underway.

Provided support for the medicines information pharmacists email discussion group.

The COSP also: provided support for publication of the Australian Medicines Information Training Workbook; provided comments to SHPA on required references for pharmacies as planned by the Pharmacy Board of Australia; and considered potential content for competency frameworks for practice in medicines information.

Mental Health

Members: Christine Culhane (Chair, Vic.), Megan Middleton (convenor), Susan Melbourne (Vic.), Diane Walters, (Vic.), Michelle Hooper (Vic.), Alice Kochman (Vic.), Christopher Alderman (SA), Carole Ramsay (SA), Sue Bascombe (WA), Denise McConnell (Qld), Judith Longworth (NSW), Virginia Bear (NSW), Donna Blomgren (NSW), Timothy Chen (NSW), Cecilia Bjorksten (corresponding member).

Outcomes for 2011/12: the COSP had three teleconferences and one face-to-face meeting during the year. The COSP completed a review of the SHPA Standards for the practice of psychiatric pharmacy, which have been adopted by Federal Council and published in JPPR June 2012 as Standards of practice for mental health pharmacy; organised a pre-conference seminar for Medicines Management 2012; networked and engaged mental health pharmacists nationally in the activities of the COSP and the email forum; investigated educational opportunities for mental health pharmacists; developed relationships with professional bodies working in mental health; considered the research focus for the network of mental health pharmacists; appointed a contributor to DrugScan section of JPPR; involved in planning and implementation of the


PSA Mental Health Strategy; acknowledged research activities of pharmacists working in mental health; and set COSP goals for future activities.

Paediatrics

Members: Sean Turner (Chair, SA), Ian Coombes (convenor), Sonya Stacey (Qld), Rachel Worthington (NSW), Antun Bogovic (Vic.), Lewis Bint (WA), Amy McKenzie (Tas.).

Outcomes for 2011/12: the COSP convened an advanced level paediatric workshop prior to Medicines Management 2011; continued to provide an avenue for communication via PaedPharm – the paediatric email group; under Sonya Stacey’s leadership the COSP continued to have input into the development of a competency framework for paediatrics; commenced planning for a clinical seminar in paediatrics to be run in Brisbane, September 2012; continued to be a reference group for paediatric issues referred by Federal Office.

national rural networkpromoting and supporting rural pharmacy practiceThe SHPA national rural adviser is Anne Leversha. Her role is to provide advice to Federal Council on rural issues that affect hospital pharmacy, to promote rural hospital pharmacy and a network of rural hospital pharmacists. Anne also represents rural hospital pharmacy at appropriate forums, and on the Allied Health Professions Australia Rural and Remote.

The rural network has representatives from the states/territories. Membership of the network consists of Anne Leversha (Chair), Frank Andinach (WA), Kara Milne (NT), Robert Forsythe (Qld), Ian Mawbey (NSW), Chris Turner (Vic.), Suzette Seaton (Tas.) and Philip Selby (SA). All members also have proxy representatives to ensure continuing representation for their sector. Contact your State representative with ideas on how your Rural Network can work for you.

The group meets three times a year by teleconference, and all SHPA members can keep up to date by reading the minutes which are posted on the SHPA website.

Branch Committees are strengthening links with the state rural representatives, and all rural pharmacists are encouraged to provide feedback on rural issues to the state representative, or to the federal adviser.

The network held a successful meeting at the Medicines Management 2011 Conference in Hobart.

national pharmacy technician networkMembers: Becky Walsh (Chair, NSW), Jackie Abercrombie (Vic.), Joan Semmler (Qld), Judy Manning (SA & NT), Paula Caird (WA), Rosemarie Oblimar (ACT).

During 2011/12, the Technician Network:

participated in Medicines Management Conference organising committees:

MM2011 Tasmania (Becky Walsh, Jackie Abercrombie): facilitated the Technician Network Breakfast at 2011 which provided pharmacy technician attendees with a great opportunity to network and discuss issues relevant to pharmacy technicians;

MM2012 ACT (Rosemarie Oblimar);

MM2013 QLD (Joan Semmler);

was represented by Judy Manning who participated in 2011 SA & NT State Branch Autumn Symposium encompassing a unique pharmacy technician program;

was extensively involved with the Community Services and Health Industry Skills Council (CS&HISC) review of the Certificate III and IV Hospital/Health Services Pharmacy Support qualifications. Becky Walsh was nominated as Chair of the Industry Reference Group for this project. The year-long review, conducted as part of ongoing improvement by the CS&HISC has lead to significant changes to the qualifications. This important work was carried out with SHPA members represented on the IRG, including substantial and invaluable input from Karen O’Leary and support from the NPTN. Early in 2012 the CS&HISC commenced a streamlining project which will also apply the Certificate III and IV Hospital/Health Services Pharmacy Support qualifications. SHPA is represented on the Streamlining Project IRG by Becky Walsh. SHPA members, Karen O’Leary and the NPTN will also provide input and support to this project.

embarked on a major project to provide technician-focused CPD content online for members through the SHPA website.


research and developmentThe Research and Development Grants Program fosters pharmacy practice by providing financial grants to SHPA members for undertaking research and/or professional development. The Program is administered by the Research and Development Grants Advisory Committee (RDGAC) which is currently based in South Australia. Members include Anna McClure (Chair-currently on maternity leave), Manya Angley (Acting Chair), Helen Lovitt (Convenor), Greg Roberts, Joy Gailer, Sepehr Shakib and Luke Grzeskowiak. The Committee is grateful to Della Absalom from the SHPA Federal Secretariat for the excellent support she provides the committee.

publicationsfacilitating professional development through quality publications

Members of the Publications Reference Group at 30 June 2012 are Megan Middleton (Chair) and Amber Roberts (Supporting Councillor) and SHPA CEO and staff Nicki Burridge and Natalie Collard.

The fifth edition of the Australian Injectable Drugs Handbook (AIDH) was published in July 2011 and a second reprint in October 2011. Over 5000 copies have been sold. The 5th edition of the AIDH is also available as an electronic version marketed through Health Communications Network Ltd to health departments and other interested healthcare organisations. Amended and new monographs are able to be downloaded from the SHPA website.

The first edition of the Australian Don’t Rush to Crush Handbook: Therapeutic options for people unable to swallow solid oral medicines was published in December 2011. Almost 1000 copies have been sold. An electronic version will be available on eMIMS and MIMS online later in the year.

The NSW Medicines Information Special Interest Group has developed the Australian Medicines Information Training Workbook. The first edition of the workbook was published in August 2011 and an online version is available for SHPA members from the SHPA eCPD website.

Work has begun on a new edition of the Australian Drug Use Evaluation (DUE) Starter Kit. It will be available in November 2012.

Grants Awarded Total Value RecipientsAuditmaker Clinical Audit Grant 2011 – Cameron Phillips, David Ellis $5,000 2

Celgene Information Technology in Hospital Pharmacy 2011 – Luke Grzeskowiak $10,000 1

Merck Sharp & Dohme Pharmacy Postgraduate Study Grant 2011 - Angela Team Yee Poon, Elena Saunders, Ashley Symonds, Meredith Crook, Chia Khee (Jackie) Kho

$20,000 5

Pfizer Pharmacy Grant 2011 - David Kong, Rachael Worthington, Sonia Koning, $10,000 3

Fresenius Kabi Cancer Services Pharmacist Grant 2011 - Midori Nakagaki, Ben Stevenson $10,000 2

Roche Research Grant on ‘Safety and Quality’ 2011 - Arti Thakerar, Rebekah Moles $10,000 2

DBL Hospira Young Pharmacist Award 2012 – Alice Kochman $10,000 1

DBL Hospira Pharmacist Award 2012 - Thuy Bui $10,000 1


journal of pharmacy practice and researchThe Journal of Pharmacy Practice and Research supports the development of hospital pharmacy practice by providing a forum for the exchange of knowledge, ideas, commentary and professional opinion for stakeholders. The Journal published quarterly in March, June, September and December, is highly valued by SHPA members. The Journal is a source of CPD material and features editorials by Australian and international opinion makers, articles on contemporary research and pharmacy practice, case reports, review articles on topics relevant to geriatric therapeutics, SHPA practice standards and guidelines, letters and book reviews.

Managing Editor, Benafsha Khariwala coordinates production of the Journal with input from the Associate Editors, Dr Manya Angley, Dr Rhonda Clifford, Professor Andrew McLachlan and Dr Jason Roberts; Specialist Section Editors, Vaughn Eaton (DrugScan) and Penny Thornton (Medication Safety); Editor, Professor Jo-anne Brien; and Administrative Assistant, Marlene Cartlidge.

The Geriatric Therapeutics’ review articles would not be possible without the commitment of the Geriatric Therapeutics Editorial Committee comprising of Associate Professor Michael Woodward (Chairman), Dr Stephen Campbell (geriatrician), and pharmacists Rohan Elliott, Francine Tanner, Robyn Saunders and Graeme Vernon.

In 2011 we bade farewell to our Associate Editor of six years, Neil Cottrell, who is pursuing other exciting opportunities that have arisen in his professional life.

Thanks to all those who supported the Journal in 2011/12, especially our contributors and expert referees who despite being busy professionals, voluntarily gave their time.

shpa branchesAustralian Capital Territory

ACT Branch committee members: Miriam Lawrence (Chair), Natalie Bula (Vice-Chair), Anthony Lamproglou (Secretary), Amy Legg (Minutes Secretary), Claire Bekema (Communications), Liisa Nurmi (Treasurer), Karlee Johnston (CE Coordinator), Fallon Grieve (CE team), Li Meng Wong (CE team), Rosie Oblimar (Technician Representative), Mark Aspden (Graduate Representative), Effy Constantinou (CASPA representative), Emily Diprose (Federal Councillor).

Advocacy, workforce and membership activities: ACT Branch members represent both major hospitals in Canberra. A high percentage of ACT hospital pharmacists and those working in related fields are SHPA members. This demonstrates the high regard for SHPA membership within the ACT, as does the willingness of local members to members to contribute to SHPA’s objectives through their work on Federal Council, Branch Committees, Committees of Specialty Practice (COSPs), and Special Interest Groups (SIGs).

The Branch awarded several grants to financially assist ACT members presenting at Make Your Move, Medicines Management 2011, the 37th SHPA National Conference. As Canberra prepares to host ACTion and Influence, Medicines Management 2012, the 38th SHPA National Conference, the conference committee has been working hard to present an exceptional scientific and social program.

In 2012 the Branch created a communications position on the committee. The aim is to improve communication with local members by publishing a quarterly newsletter highlighting branch activities and upcoming CE events.

Advocacy: the Branch continued its strong relationship with University of Canberra Pharmacy School in 2011/12. Quality Use of Medicines research prizes were awarded to two UC students; Julia Hurz for her Health Literacy project Assessing the Readability, Suitability and Understanding of Consumer Information; and Simon Edwards for his Meropenem Drug Usage Evaluation. The ACT Branch additionally provided lucky door prizes for the University of Canberra Pharmacy School ball, donating two Don’t Rush to Crush books and one SHPA student membership.

The Branch has also added student and graduate representatives to the Branch committee in 2012.

Educational activities: the annual ACT Branch Symposium was an Antibiotic Update held in September 2011. Presentations covered new and emerging infections, principles of antibiotic use and resistance, antimicrobial stewardship across the ACT, local infection control issues and pharmacokinetics and pharmacodynamics of antiinfectives. This event was very well attended and feedback from attendees was extremely positive. Other successful monthly CE topics have included management and surveillance of communicable disease outbreaks, vitamin D and IV lines update.

In 2012 the branch redesigned the coordination of CE for ACT members by forming a ‘CE Team’ including a CE coordinator and additional CE team members to assist in the organisation of events. There was also a trial of alternate CE session times to suit members who were unable to attend the traditional evening sessions.

Special achievements or news: in 2011 the ACT Branch undertook a new CE initiative specifically for pharmacy technicians to promote SHPA membership to ACT pharmacy technicians. Three sessions were held covering topics such


as anatomy and physiology, ward technician services and nutrition. Feedback on these sessions was overwhelmingly positive. In 2012 the committee will be surveying local technicians to gauge ongoing interest in joining SHPA as technician members as well as their understanding of SHPA member benefits and potential future CE topics. The survey results will inform future plans for technician specific SHPA CE and engagement in the ACT.

Special thanks goes to Joanne Wilson who finished her three-year term on the committee at the end of 2011. Jo’s contribution as Vice Chair was highly valued, as is her ongoing involvement on the MM2012 Conference organising committee. We would also like to thank Anthony Lamproglou who resigned from the committee in June 2012 due to other commitments. Anthony did a great job as Branch Secretary for the two years he sat on the committee. ERANCH.....NSW

BRANCH..... New South Wales

NSW Branch committee members: Kate Oliver (Chair), Peter Barclay (Vice-Chair), Daniel Lalor (Secretary), Kerry Davison (Treasurer), Jonathan Penm (Newsletter Editor), Helen Dowling (Industry and Professional Liaison), Lisa Pont, Natalie Tasker, Ann Carter (Dec 2011 to April 2012), Zahid Ghous (from June 2012), Karen Kaye (Federal Councillor), Sasha Bennett (Federal Councillor), Ian Mawbey (Rural Observer), Becky Walsh (Technician Observer), Sarah Bowen (Pharmacy Intern Observer, 2011), Michelle Vine (Pharmacy Intern Observer, 2011), Christine Wasef (Pharmacy Intern Observer, 2012), Kelvin Cao (Pharmacy Intern Observer, 2012), Jonathon Perry (Student Observer, 2011), Katrina O’Brien (Student Observer, 2011), Chris Loupos (Student Observer, 2012), Mark Sheppard (Student Observer, 2012).

Advocacy, workforce and membership activities: a major focus of the NSW Branch over the 2011/2012 financial year has been to increase the number of student members of the Branch. With several new pharmacy schools opening in the state, the Branch sought to get hospital pharmacy firmly in the minds of students, demonstrating to them the vast array of opportunities that exist.

Becky Walsh, the Branch Technician Observer, has been instrumental in work undertaken by the Community Services and Health Industry Skills Council to review certificate three and four qualifications for pharmacy technicians. The evolving and developing role of pharmacy technicians was not adequately reflected in the existing certificate courses and, with Becky’s considerable contributions, these qualifications and associated courses have been revised.

Edited by Jonathan Penm, the Branch newsletter continues to be a rich source of information for members and solid mechanism for communication on important issues. Four editions have been issued in this reporting period, each well received.

Advocacy was continued via liaison with the following bodies: Pharmacy Board of NSW Statewide Medication Safety Committee Pharmaceutical Society of Australia (NSW Branch) University of Sydney Directors of Pharmacy of NSW Teaching Hospitals Newcastle University Allied Health Alliance Charles Sturt University NSW Health: The Area Pharmacy Advisors Group Faculty of Pharmacy Alumni, University of Sydney

Educational activities: the NSW Branch continued to provide monthly continuing education opportunities for members. Monthly meetings held at Concord Hospital were well attended and covered topics including updates on complementary medicine-drug interactions, the management of chronic pain, new developments in COPD and a fascinating review of polypharmacy in mental health. The monthly CE meetings continue to be a great opportunity for networking and cross-fertilisation of ideas as well as learning about the cutting edge in pharmacotherapeutics and ways in which hospital pharmacists may address day-to-day work issues.

This regular program was supplemented by the annual clinical symposium, which provided an update on neurology. This symposium was very well attended and provided exceptional value for attendees. High-calibre speakers combined with exceptional case reports presented by members made the day a value CPD event on the NSW Branch calendar.

In this reporting period, the Branch has established strong links with NSW Pharmacy Educators Group. This group was established to facilitate networking between pharmacists employed specifically as educators across the state. These positions were established in response to the recommendations of the Special Commission of Inquiry into Acute Care Services in NSW Public Hospitals. The Pharmacy Educators Group now also includes the NSW SHPA Branch Education Coordinator. This valuable link enables the Branch to ensure that the continuing education program of the Branch is as closely matched to the needs of members as possible.

The Branch continues to establish links with pharmacy schools throughout NSW. Representatives of the Branch have presented at numerous information sessions at the University of Sydney, Charles Sturt University and the University of Technology, Sydney. These sessions have included information about what it means to be a hospital pharmacist as well as practical sessions on how to approach applying for intern positions. These sessions have been very well received which is evident in the large number of student members that have joined the Branch.

Special achievements: during this financial year, the Branch received the commissioned report on the status of clinical pharmacy services in NSW. This report was part of a project funded by the Branch to establish the ways in which pharmacy departments had or could use the funding made available following the Special Commission of Enquiry into Acute Care Services in NSW Public Hospitals. Findings from this project will be of significant benefit to pharmacy departments across NSW in demonstrating the value for money that investment in pharmacy services represents. The Branch is actively working to establish the best ways in which the findings from the project can be implemented and will play a key role in support pharmacists to advocate for the further development of clinical pharmacy services within NSW hospitals.

Special thanks go to: Dr Rebekah Moles has been a longstanding contributor to the activities of the NSW Branch through her role as a Federal Councillor. Rebekah’s term as a federal councillor ended in 2011. The Branch is indebted to Rebekah for the valuable contributions that she made during this time. The Branch also loses Helen Dowling from the Branch Committee. Helen has been a leader of the pharmacy profession in NSW for many years and has contributed significantly to a number of organisations including the Pharmacy Council and ACHS. Helen has been at the forefront of current reforms in the NSW public health care system and has always advocated strongly for the role of the hospital pharmacist. Helen will be sorely missed by the Branch and we wish her well as the new CEO of SHPA.


The NSW Branch also wishes to thank the Pharmacy Department, Concord Hospital and particularly Rosemary Burke who have facilitated the use and availability of the Concord Hospital Clinical School Lecture Theatre and its amenities such as videoconferencing. After many years at Harold Park, the CE has effected transition to Concord and CE attendee numbers continue to grow.

The NSW Therapeutic Advisory Group (NSWTAG) has provided a venue for monthly branch committee meetings along with teleconferencing hardware and a postal address. SHPA NSW Branch wish to thank NSWTAG for their continued support.

Queensland Qld Branch committee members: Jason Roberts (Chair), Kelly Mulvogue (co-Vice-Chair), Arna Neilson (co-Vice-Chair), Lee Allam (Secretary), John Parke (Treasurer), Jackie Costello (Minutes Secretary), Elizabeth Currey (CE Coordinator), Jess Lloyd (CE Coordinator), Jackie Costello (Newsletter Coordinator), Andy Lo (Newsletter Coordinator), Lynette Loy (Rural and Remote), Tony Hall (Federal Councillor), Ian Coombes (Federal Councillor), Joan Semmler (Technician Observer), Tina Ha (Observer Asst. Sec.), Bryson Swan (Rural and Remote Observer), Margaux Tuqiri (Intern Observer), Emma Alder (Observer).

Representation and liaison: Queensland Branch liaises with the Queensland branches of the Pharmaceutical Society of Australia and the Pharmacy Guild of Australia; SHPA Queensland Branch members continue to represent SHPA in a number of fora and government committees; viz. John Parke is a representative on the Pharmacists Board of Queensland, Ministerial Advisory Committee for Clinical Training and Education, and with Tony Hall sits on the Queensland Health Pharmacy Advisory Committee; Jason Roberts sits on the University of Queensland Postgraduate Diploma in Clinical and Hospital Pharmacy Management Committee and the Queensland Health Drug Therapy Protocol Steering Group.

The SHPA Queensland Branch provided continued support in terms of representation on relevant Board of Studies Committees and by providing awards to students that demonstrate outstanding clinical pharmacy skills.

Educational activities: our CE events have continued to be well attended, and the slides and audio recordings of these events have been the mainstay of the ‘CE on CD’ initiative from Federal Office. Queensland continues to be a leader in Australia with its videoconferencing which enables up to 150 pharmacists (at times), to participate from over 25 sites throughout Queensland and northern NSW. We thank all our presenters for donating their time for another highly successful year.

Our most recent CE initiative is led by Andy Lo and involves internet streaming via “GoToMeeting” of our CE events to those unable to attend the host site or a videoconferencing site in person. This system has been trialed and has been very successful, with up to 40 members being able to access the CE via Smartphone, Computer or iPad.

We will look to continue to optimize this form of CE delivery and potentially deliver our CE Australia-wide. Already this year, we had a SHPA member link into one of our CE sessions from France!

Our thanks must also go to Liz Coombes (Director of Pharmacy, Gold Coast Hospital), who collaborates with PSA Queensland to organise an extensive CE program on the Gold Coast. Robyn Underwood (Director of Pharmacy, Townsville) facilitates a similar program in Townsville. Both continue to also provide excellent support to Griffith University and James Cook University Pharmacy programs respectively.

Special thanks go to: Members leaving the committee during the year were Heidi Wong, Fran Golding, Jaana Baker, Jill Upton and Wendy Thompson. We are grateful for their hard work.

Thanks to Andy Lo and Jackie Costello for their development of a new format for the newsletter. This has continued to be an important vehicle for dissemination of information to SHPA members and the committee will endeavor to further improve this product.

SHPA Federal Councilors continue to volunteer their time and attend the Queensland Branch Meetings. Tony Hall and Ian Coombes perform a wonderful role of representing the interests of pharmacists and technicians on the Federal Council and ensure that Queensland receives updates of the themes of Council activities. This allows the Queensland Branch to be very progressive and continue to offer wonderful benefits to Queensland SHPA Members.

South Australia and Northern Territory

SA & NT Branch committee members: Richard Marotti (Chair), Sean Turner (Vice-Chair), Hayley Vasileff (Secretary), Cher-Rin Chong (Minutes Secretary) Hamed Shahnam (Treasurer), Luke Grzeskowiak (Continuing Education), Alicia Thomas (Continuing Education), Albert Michail (Continuing Education), Rachael Cheh (Public Liaison), Catherine Hughes (Federal Councillor), Angela Young (NT Advisor), Petra Straight (NT Advisor), Judy Manning (Technician Observer), Wanda Haines (Technician Observer), Sarah Crossing (Technician Observer), Matthew Schanbl (Intern Observer), Julie Tran (Intern Observer), Sheree Wynne (Student / SAPSA Observer).

Advocacy, workforce and membership activities: this year we have continued to encourage access of members to the Branch committee by rotating meetings between the various hospitals within Adelaide. We have been fortunate to have respective Directors of Pharmacy in attendance at these meetings as well as some staff members.

A hospital pharmacy information day was held in October in conjunction with SAPSA at the University of South Australia with approximately 150 students attending the “Q & A” type forum.

This year the Branch has for the first time a student representative from SAPSA. This has been a valuable addition to the committee and certainly enhanced the relationship between SHPA and student body.

The Branch has also been active in advocating for hospital pharmacy to SA Health as a comprehensive pharmacy services review progresses this year.


Advocacy was continued via liaison with the following bodies: Pharmacy Guild of Australia (SA) Charles Darwin University SHPA Rural Network University of South Australia Pharmaceutical Society of Australia (SA) Allied Health Professionals of South Australia (AHPSA) Educational activities: the delivery and access of CE material has continued to develop and maintain a very high standard. The development of learning objectives and the subsequent accreditation of each session has now become an essential component to the delivery of high quality CE. Videoconference facilities to Alice Springs and rural South Australia have become regular occurrences and continue to provide our rural members with access to monthly CE activities. Feedback received from each of the monthly CE sessions continues to be extremely positive.

The 4th Autumn Symposium was held in May at the University of South Australia and was a fantastic success, with approximately 100 people attending. The symposium covered a range of clinical and non-clinical topics including collaborating with the pharmaceutical industry, palliative care, antipsychotics and a clinical trial design hypothetical. This year’s symposium also saw the continuation of contributed short case presentations, following on from last year’s successful ADR case studies. However, this year, expressions of interest from new presenters were called for across the whole membership. The clinical case presentations were a particular highlight of this year’s symposium. Emma Brown (LMH), James Banh (LMH), Courtenay Wilson (LMH), Clare Smith (TQEH) and Tanja Trbovic (LMH) were selected from a large group to present based on excellent submissions. All presented cases were of a very high standard. Congratulations go to Tanja and Emma who were awarded the Expert Panel and People’s Choice awards respectively. There was also a poster session this year which was a chance for delegates to showcase their posters, which may have been presented at various conferences but have not been shown at a local level.

A dedicated technician program was delivered by a host of expert presenters and included hands on as well as theoretical content. Feedback was very positive. The majority of the participants strongly agreed or agreed (87%) that the global objectives were achieved. Participants commented positively on the selection of topics, venue and speakers. The inclusion of contributed clinical case presentations and use of audience response devices (i.e. clickers) received overwhelmingly positive feedback.

Thank you to co-convenors Jo To and Adam Phillips, as well as the organising committee and advisory group, who were responsible for putting on such an excellent symposium

Special thanks go to: The branch would like to thank and recognise the tireless work of Sharon Goldsworthy who has represented the SA & NT branch on Federal Council for a number of years.

Tasmania

Tas. Branch committee members: Duncan McKenzie (Chair), Tom Simpson (Vice-Chair), Camille Boland (Secretary), Jane Frankling (Treasurer), Amber Roberts (Federal Councillor), Leanne Chalmers (CE Coordinator), Sharon Gordon-Croal, George Taylor, Suzette Seaton, Oummy Tepkumkun.

Advocacy, workforce and membership activities: many Tasmanian members are active in the Clinical Pharmacy COSP, chaired by George Taylor. Duncan McKenzie is the Tasmanian representative on the shpaclinCAT Reference Group and is a committee member of the Infectious Diseases COSP. Leanne Chalmers is an AHPRA examiner. The Branch has also kept close links with the University of Tasmania School of Pharmacy, including the tradition of visiting undergraduate students at the school to showcase hospital pharmacy. The Branch also provides support for the 3rd and 4th year Clinical Pharmacy prizes. The Tasmanian Branch also has two student observer members, (currently Matthew Luciani and Bronwyn Jones) who liaise with the Tasmanian Pharmacy student body (TAPS) with regard to SHPA activities.

Advocacy was continued via liaison with the following bodies: University of Tasmania School of Pharmacy PDL Local Advisory Committee Course Advisory Committee shpaclinCAT Reference Group SHPA Rural Network

Educational activities: the Medicines Management Conference 2011 was held in Hobart in November and organised by a team which included many Tasmanian Branch members. The Tasmanian Branch Annual Symposium was held on 18-20 May 2012. The Symposium, entitled ‘Gastroenterology and Professional Communication’ was attended by 33 pharmacists, 7 interns/students and 20 industry representatives. The keynote speakers were Dr Grant Phelps who spoke on “VTE Prophylaxis: Where Are We Now?” and “Engaging with Clinicians - Tips and Traps”, and Dr Kwang Chien Yee who presented three presentations - “Gastroenterology Update 2012”, “Clinical Handover” and a refresher and interactive workshop on “LFTs for Pharmacists”. The keynote presentations were complemented by a range of papers on diverse topics presented by local members.

Special thanks go to: all members involved in the successful 2011 Medicines Management Conference held in Hobart, with special recognition to the co-convenors Amber Roberts and Tom Simpson for their amazing commitment. Thanks should also go to Leanne Chalmers for her tireless efforts in promoting and coordinating continuing education for Tasmanian members.

Victoria

Vic. Branch committee members: Helen Matthews (Chair), Alice Kochman (Vice Chair), Kirstie Galbraith (Secretary), Jo Edwards (Agenda Secretary), Leith Lilley (Minutes Secretary), Kerryn Barned (Associate Minutes Secretary), Glenn Valoppi (Treasurer), Patrick Lam (Newsletter Editor), Sonia Koning (CE Coordinator), Gillian Swinnerton (Membership), Cathy Ingram (Technician Observer), Megan Middleton (Federal Councillor), Sue Kirsa (Federal Councillor), Sally Yeung (Pharmacist Project Officer).


Advocacy, workforce and membership activities: Membership growth has been constant for pharmacists, interns and technicians in private, public and community sectors. The Intern and student placement program, organised by Sally Yeung, places 88 interns annually, commencing with advertising the process in April 2012. The 2012 Bachelor of Pharmacy third year exhibition, Master of Clinical Pharmacy Prize, Monash University, and third year prizes at Latrobe University were presented.

Advocacy was continued via liaison with the following bodies: Victorian Department of Health Latrobe University Pharmacy School Australian Health Practitioner Regulation Agency RMIT University Faculty of Pharmacy Pharmaceutical Society of Australia Victorian Branch National Alliance for Pharmacy Education Monash University Faculty of Pharmacy and VicTAG Pharmaceutical Sciences Educational activities: The Victorian CE program, organised by Sonia Koning, and the annual Victorian Managers Meeting, convened by John Evans, were both well attended. The Victorian Summitt 2011, organised by Jenny Tio and her committee, showcased SIG and COSP work by specialists in the fields of renal, women’s health, outreach services, pharmacy technician practice, oncology, educational visiting and IT development.

Special thanks go to: Melita Van de Vreede for her great support on the Victorian Branch as Secretary and Vice Chair; and to Bill Thomson for his cooperation and hard work in archiving the Victorian Branch records.

Special Interest Groups: Thanks also go to the chairs of these Special Interest Groups: Mental Health – Sue Melbourne; Oncology – Jim Siderov; Outreach – Lavinia Verducci; Renal – Michelle Nalder; General Medicine – Sheue-Ching Ooi.

Western Australia

WA Branch committee members: Matthew Foster (Chair), Stephen Lim (Vice-Chair), Peter Smart (Secretary), Brenda Shum (Treasurer), Zeyad Ibrahim (Communications Manager), Cameron Wright (CE Coordinator), Michelle Luca (CE Coordinator), Yang Liu (CE Coordinator and Membership Coordinator), Kerry Buchan (Minute Secretary), Paula Caird (Technician Representative), Helen Lovitt (Federal Councillor), Stacey Gough (Intern Representative), Flavia Nguyen (Intern Representative).

Advocacy, workforce and membership activities: the WA Branch has worked to advocate and increase awareness of the value of pharmacists within our health system. One such effort was a submission to the WA Health Department in relation to the WA Primary Health Care Strategy. Our membership strategy has been implemented with membership promoting emails being distributed to multiple community pharmacies and newsletter distributions to rural pharmacy departments. Our focus on intern and student members has been honed to allow our intern representatives the time and resources to promote SHPA to graduating students. Our CE Coordinators have promoted the benefits of SHPA to rural members by organising real-time projection of CE events to hospital departments all over this huge state.

Advocacy was continued via liaison with the following bodies: ■ Oncology Nurses and Pharmacists Interest Group ■ WA Clinical Oncology Group ■ Health Department of WA ■ WA Medication Safety Group ■ University of Western Australia ■ WA Pharmacy Students Association ■ Curtin University ■ Pharmaceutical Society of Western Australia.

Educational activities: our CE Coordinators have organised an array of CE events with a broad range of topics which are relevant and current.

This year we were fortunate enough to have two half day seminars. August 2011 we focused on transplants with topics of haematological transplantation, solid organ transplants, patient perspectives and opportunistic infections. In June 2012 the topic was acute pain management with pain specialists from multiple disciplines discussing the intricacies of this very common issue. With case study presentations and panel discussions the audience interaction was very encouraging. Both of these events were very well organised by the CE Coordinators with the half-day seminar sub-committee support.

Special thanks go to: All half-day seminar subcommittee members including Penny Tuffin and Anna Gelavis. All Branch Committee Members who served during 2011 including Chris Hopps, Sarah Heward, Katherine Travers, Jeanie Misko, Brenton Tenaglia and Katrina Martin.


from the treasurer - annual financial report 2011/12Summary and Comparison of Financial Results Financial Year Income Net Result1993/94* $1,467,380 $120,0351994/95 $1,339,753 ($27,990)1995/96* $1,891,163 $9461996/97 $1,468,248 $85,8651997/98* $2,135,227 $65,5611998/99 $1,420,028 ($160,595)1999/00* $1,705,718 $46,2632000/01 $1,655,197 $85,8692001/02* $1,857,487 $125,7612002/03 $1,731,177 $283,1422003/04* $2,149,140 $232,2602004/05# $1,921,086 $383,2572005/06* $2,430,574 $372,8082006/07 $2,228,239 $261,8122007/08* $2,385,739 $273,0902008/09* $2,606,595 $349,5152009/10* $2,609,009 $409,3502010/11* $2,854,177 $178,5532011/12* $3,300,949 $437,344

The 2011/12 financial year has been another successful one for SHPA with a positive financial result in addition to expanding and enhancing member services.

SHPA appointed a Research into Practice pharmacist with the support of Celgene via an unrestricted research grant. This role has enabled SHPA to produce Medicines in Focus fact sheets which concisely summarise the available evidence for the ways that pharmacists can improve medicines management. Expenditure on publications has increased with the release of two new titles and SHPA also invested in a new server.

Revenue has grown with membership increasing from 2865 at 30 June 2011 to 3048 at 30 June 2012, sales of the fifth edition of the Australian Injectable Drugs Handbook (AIDH) and first edition of the Australian Don’t Rush to Crush Handbook (DRTC). SHPA has been fortunate to receive financial support for the shpacpd program from our education partners Celgene and Roche. SHPA seminars continue to enjoy sponsorship of the program, as a whole, from Pharmaceutical Defence Limited (PDL).

The favourable financial result for this year was greater than anticipated mainly due to: substantial increase in membership numbers, larger than anticipated attendance at Medicines Management Hobart 2011, early sales of the new edition of the AIDH and the finalisation and launch of DRTC. Financial gains will continue to be reinvested in membership services in 2012/13.

Anthony Hall, Federal Treasurer

* Federal Conference years# includes one-off capital gain

-$500,000

$0

$500,000

$1,000,000

$1,500,000

$2,000,000

$2,500,000

$3,000,000

$3,500,000

$4,000,000

$4,500,000

$5,000,000

1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012

Federal results Branch results Operating profits before tax Members' funds (retained profits)


directors’ reportYour directors present their report on the company for the financial year ended 30 June 2012.

directors Commenced Ceased Number of meetings as councillor as Councillor Attended Eligible to attend

Alexandra (Sasha) A Bennett 13 Nov 2011 5 5 Natalie J Bula 2010 13 Nov 2011 1 2 Ian D Coombes 2009 7 8 Emily Diprose 13 Nov 2011 4 5 Sharon J Goldsworthy 2005 13 Nov 2011 2 2 Anthony D Hall 2004 4 6 Catherine Hughes 13 Nov 2011 4 5 Karen I Kaye 2007 4 6 Suzanne W Kirsa 2009 6 6 Helen A Lovitt-Raison 2007 5 7 Megan F Middleton 2008 5 6 Rebekah J Moles 2003 13 Nov 2011 3 3 Amber L Roberts 2005 5 6

principal activitiesThe principal activity of SHPA during the financial year was to provide services for members to enhance their ability to improve health outcomes for individuals and the community. This includes a broad range of activities from continuing professional development (CPD) for members to working with governments to support the safe and effective use of medicines by individuals, the community and other health professionals.

SHPA’s short-term objectives are: To improve the understanding of the pharmacist’s input to the safe and effective use of medicines in particular through: the national safety and quality agenda, National Medicines Policy, national e-health activities, National Health and Hospital Reform; To enhance the effectiveness of existing relationships and to develop new key partnerships with consumers and other health professionals involved in medicines management; To support the competency and effectiveness of the hospital pharmacy workforce and so support better outcomes for consumers ; To provide valued services to all SHPA members in all membership categories, taking account of the needs of members in rural and remote areas and to be the organisation of choice for pharmacists, irrespective of their pharmacy practice setting; and To increase understanding of CPD within SHPA membership and provide a range of educational and development activities and products to support the needs of all SHPA members.

SHPA’s long-term objectives are to:

Support the continuing professional development of our members; Have strong membership within hospitals and all other quality use of medicines settings; Partner with key medicines stakeholders; and Advocate for the safe and effective use of medicines across the continuum of care to improve health outcomes for consumers.

To achieve these objectives, SHPA has adopted the following strategies during the year:

Participated in consultations, meetings and provided submissions on key National Health and Hospital Reform initiatives, prescribing competencies, advanced pharmacy practice, hospital funding, national e-health, home medicines reviews, accreditation of pharmacy schools and numerous similar activities. SHPA has raised the crucial place of using medicines in contemporary health care, especially in chronic disease management. Deadlines were met for all submissions. Continued training pharmacists as shpaclinCAT evaluators who could then implement the competency assessment tool into workplaces to enhance the professional development of individual pharmacists. This prime focus was for pharmacists to improve their skills, but benefits flow to managers, the profession and importantly the consumers who use our services and expect a competent workforce. Further broadened the choice of CPD activities and modalities that are available as core member benefits, being mindful to include a range of activities so there is something suitable for pharmacists in any practice setting. This has provided many Group 2 CPD activities for members via CD, JPPR, online case studies and e-learning modules on the Moodle website. Published the planned four quarterly Journal of Pharmacy Practice and Research to continue to enable and encourage the publication of research and other papers from pharmacists to enhance the evidence base on which our services are provided. Published the 5th edition of the Australian Injectable Drugs Handbook, 1st edition of the Australian Don’t Rush to Crush Handbook and the 1st edition of the Australian Medicines Information Training Workbook. E-learning modules based on the Australian Don’t Rush to Crush Handbook and Medicines Information Training Workbook have been developed and utilised by members. These publications to varying degrees provide important income streams for SHPA, however, their prime function is to provide resources that can be used by health professionals. Communicated with members using a range of methods including weekly e-newsletters, quarterly SHPA Bulletin, social media and the SHPA website.


information on directors

auditor’s independenceThe lead auditors’ independence declaration for the year ended 30 June 2012 has been received and can be found on page 27 of the financial report.

Signed in accordance with a resolution of the Board of Directors.

Suzanne W Kirsa (Director)Dated 7th September 2012

Qualifications

BPharm, GradDipHospPharm, FSHP

BPharm, MBA

BPharm (Hons), AdvDipClinPharmTeach, DipMedSci (PallCare), FSHP

BPharm, DipHospPharm, GradCertPharmacoeconomics, FSHP

BPharm, DipHospPharm, GradCertClinPharm, PhD, FSHP, AACPA

BPharm, DipMan, GradCertMan

BPharm, PhD, MSc

BPharm (Hons)

BPharm, MClinPharm, FSHP

BPharm

BPharm, GradDipPharm, FPS (WA)

BPharm (Hons)

BPharm, DipHospPharm, PhD, GradCertEdStudies (Higher Ed), FSHP

Experience

Director of Pharmacy, Peter MacCallum Cancer Centre, Vic.

Statewide Medication Coordinator, Medication Strategy and Reform, Department of Health and Human Services, Tas.

Senior Lecturer, School of Pharmacy, Griffith University, Gold Coast campus, Qld; Specialist Clinical Pharmacist, Persistent Pain, Gold Coast HSD; Director Allied Health Professions Australia

Executive Manager, Programs and Services, NPS, Better choices, Better health (NPS MedicineWise), NSW

Executive Officer, NSW Therapeutic Advisory Group, NSW.

Acting Director of Pharmacy, The Canberra Hospital, ACT

Director of Pharmacy, Royal Brisbane and Women’s Hospital Adjunct Assoc. Professor, School of Pharmacy, University of Queensland

Deputy Director of Pharmacy, Calvary Health Care ACT

Director of Pharmacy; The Queen Elizabeth Hospital, SA Pharmacy

Director Country Pharmacy Services, SA Pharmacy, SA Health

Senior Pharmacist, Pharmacy Department, Fremantle Hospital and Health Service, WA

Lead Project Pharmacist, eCare@Eastern, Eastern Health, Vic.

Lecturer, The University of Sydney, NSW

Name

Suzanne W Kirsa

Amber L Roberts

Anthony D Hall

Karen I Kaye

Alexandra (Sasha) A Bennett

Natalie J Bula

Ian D Coombes

Emily Diprose

Sharon J Goldsworthy

Catherine Hughes

Helen A Lovitt-Raison

Megan F Middleton

Rebekah J Moles

Special Responsibilities(appointments for entire year unless otherwise stated)

Federal President

Vice-President 13/11/2011-30/6/2012; Supporting Councillor, Publications Reference Group

Federal Treasurer

4th Executive Member 13/11/2011-30/6/2012

Federal Councillor 13/11/2011-30/6/2012; Supporting Councillor Education Reference Group 13/11/2011-30/6/2012

Federal Councillor 1/7/2011-13/11/2011

Federal Councillor; Chair, Education Reference Group

Federal Councillor 13/11/2011-30/6/2012Supporting Councillor National Pharmacy Technician Network

Federal Vice-President 1/7/2011-13/11/2011; Chair, Publications Reference Group 1/7/2011-13/11/2011

Federal Councillor 13/11/2011-30/6/2012; Supporting Councillor, Specialty Practice Reference Group 13/11/2011-30/6/2012

Federal Councillor, Chair, Specialty Practice Reference Group 13/11/2011-30/6/2012

Federal Councillor, Chair, Publications Reference Group 13/11/2011-30/6/2012

4th Executive Member 1/7/2011-13/11/2011


auditor’s independence declarationunder S 307C of the Corporations Act 2001 to the directors of The Society of Hospital Pharmacists of Australia I declare that, to the best of my knowledge and belief, during the year ended 30 June 2012 there have been: (i) no contraventions of the auditor independence requirements as set out in the Corporations Act 2001 in relation to the audit; and (ii) no contraventions of any applicable code of professional conduct in relation to the audit.

ANDERSON AUDITORS ROBERT F. CINCOTTA Chartered Accountants Partner Level 6, 484 St Kilda Road, Melbourne VIC 3004 Dated this 7th day of September 2012 INCOME STATEMENT FOR THE YEAR ENDED 30 JUNE 2012 2012 2011 Note $ $Revenue 2 3,300,949 2,854,177 Changes in inventories of finished goods and work in progress (6,491) (4,435) Raw materials and consumables used (138,013) (13,627) Employee benefits expense (1,125,232) (959,544) Depreciation and amortisation expenses 3 (74,523) (67,339) Conference & seminar expenses (846,309) (978,526) Advertising & promotional expenses (20,544) (6,850) Printing, stationery & postage expenses (218,263) (205,975) Travelling expenses (131,972) (112,045) Computer expenses (78,812) (67,936) Consultancy fees (10,515) (26,793) Lobbying costs - (30,000) Repairs & maintenance expenses (3,412) (4,611) Other expenses (209,519) (197,943) Profit before income tax 437,344 178,553 Income tax expense - - Profit for the year 437,344 178,553 Profit attributable to members of the entity 437,344 178,553 STATEMENT OF COMPREHENSIVE INCOME FOR THE YEAR ENDED 30 JUNE 2012 Profit for the year 437,344 178,553 Total comprehensive income for the year 437,344 178,553 Total comprehensive income attributable to members of the entity 437,344 178,553 STATEMENT OF FINANCIAL POSITION AS AT 30 JUNE 2012 CURRENT ASSETS Cash and cash equivalents 4 4,343,463 3,693,133 Trade and other receivables 5 173,043 289,574 Inventories 6 6,051 440 Other current assets 7 233,707 154,600 TOTAL CURRENT ASSETS 4,756,264 4,137,747 NON-CURRENT ASSETS Property, plant and equipment 8 1,370,604 1,401,751 TOTAL NON-CURRENT ASSETS 1,370,604 1,401,751 TOTAL ASSETS 6,126,868 5,539,498 CURRENT LIABILITIES Trade and other payables 9 1,674,747 1,536,431 Short-term provisions 10 128,470 116,760 TOTAL CURRENT LIABILITIES 1,803,217 1,653,191 TOTAL LIABILITIES 1,803,217 1,653,191 NET ASSETS 4,323,651 3,886,307 EQUITY Retained earnings 4,109,074 3,671,730 Reserves 214,577 214,577 TOTAL EQUITY 4,323,651 3,886,307


STATEMENT OF CHANGES IN EQUITY FOR THE YEAR ENDED 30 JUNE 2012 Asset Retained Revaluation Profits Reserve Total $ $ $Balance at 1 July 2010 3,493,177 214,577 3,707,754 Profit attributable to members 178,553 - 178,553 Other comprehensive income for the year - - - Balance at 30 June 2011 3,671,730 214,577 3,886,307 Profit attributable to members 437,344 - 437,344 Other comprehensive income for the year - - - Balance at 30 June 2012 4,109,074 214,577 4,323,651 For a description of each reserve, refer to Note 18. STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 30 JUNE 2012 2012 2011 Note $ $CASH FLOW FROM OPERATING ACTIVITIES Receipts from customers & grants 3,930,271 3,217,699 Payments to suppliers and employees (3,453,131) (2,773,900) Interest received 217,047 176,882 Net cash generated from operating activities 15 694,187 620,681 CASH FLOW FROM INVESTING ACTIVITIES Proceeds from sale of property, plant & equipment 730 - Payments for property, plant and equipment (44,587) (54,191) Net cash provided by (used in) investing activities (43,857) (54,191) Net increase (decrease) in cash held 650,330 566,490 Cash and cash equivalents at beginning of the financial year 3,693,133 3,126,643 Cash and cash equivalents at the end of the financial year 4 4,343,463 3,693,133 NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2012 The financial statements cover The Society of Hospital Pharmacists of Australia Ltd as an individual entity, incorporated and domiciled in Australia. The Society of Hospital Pharmacists of Australia Ltd is a company limited by guarantee.

1. Summary of Significant Accounting Policies The financial statements are general purpose financial statements that have been prepared in accordance with Australian Accounting Standards (including Australian Accounting Interpretations) and the Corporations Act 2001. The company is a not-for-profit entity for financial reporting purposes under Australian Accounting Standards. Australian Accounting Standards set out accounting policies that the AASB has concluded would result in financial statements containing relevant and reliable information about transactions, events and conditions. Material accounting policies adopted in the preparation of these financial statements are presented below and have been consistently applied unless stated otherwise. The financial statements, except for the cash flow information, have been prepared on an accruals basis and are based on historical costs, modified, where applicable, by the measurement at fair value of selected non-current assets, financial assets and financial liabilities. The amounts presented in the financial statements have been rounded to the nearest dollar. The financial statements were authorised for issue on the 7th day of September 2012 by the directors of the company. Accounting Policies Revenue Grant revenue is recognised in the statement of comprehensive income when the entity obtains control of the grant and it is probable that the economic benefits gained from the grant will flow to the entity and the amount of the grant can be measured reliably. If conditions are attached to the grant which must be satisfied before it is eligible to receive the contribution, the recognition of the grant as revenue will be deferred until those conditions are satisfied. When grant revenue is received whereby the entity incurs an obligation to deliver economic value directly back to the contributor, this is considered a reciprocal transaction and the grant revenue is recognised in the statement of financial position as a liability until the service has been delivered to the contributor, otherwise the grant is recognised as income on receipt. Interest revenue is recognised using the effective interest rate method, which for floating rate financial assets is the rate inherent in the instrument. Revenue from the rendering of a service is recognised upon the delivery of the service to the customers. All revenue is stated net of the amount of goods and services tax (GST). Inventories Inventories are measured at the lower of cost and current replacement cost. Property, Plant and Equipment Each class of property, plant and equipment is carried at cost or fair values as indicated, less, where applicable, accumulated depreciation and impairment losses.


Property Freehold land and buildings are shown at their fair value based on periodic, but at least triennial, valuations by external independent valuers, less subsequent depreciation for buildings. In periods when the freehold land and buildings are not subject to an independent valuation, the directors conduct directors’ valuations to ensure the carrying amount for the land and buildings is not materially different to the fair value. Increases in the carrying amount arising on revaluation of land and buildings are recognised in other comprehensive income and accumulated in the revaluation surplus in equity. Revaluation decreases that offset previous increases of the same class of assets shall be recognised in other comprehensive income under the heading of revaluation surplus. All other decreases are recognised in profit or loss. Any accumulated depreciation at the date of the revaluation is eliminated against the gross carrying amount of the asset and the net amount is restated to the revalued amount of the asset. Plant and Equipment Plant and equipment are measured on the cost basis and are therefore carried at cost less accumulated depreciation and any accumulated impairment. In the event the carrying amount of plant and equipment is greater than the estimated recoverable amount, the carrying amount is written down immediately to the estimated recoverable amount. A formal assessment of recoverable amount is made when impairment indicators are present. Depreciation The depreciable amount of all fixed assets, including buildings and capitalised lease assets but excluding freehold land, is depreciated over the asset’s useful life to the entity commencing from the time the asset is available for use. The depreciation rates used for each class of depreciable asset are: Class of Fixed Asset Depreciation Rate Land 0% Buildings 2.50% Property Improvements 2.50% Plant and Equipment 7.5% - 100% The assets’ residual values and useful lives are reviewed, and adjusted if appropriate, at the end of each reporting period. Gains and losses on disposals are determined by comparing proceeds with the carrying amount. These gains or losses are included in the statement of comprehensive income. When revalued assets are sold, amounts included in the revaluation reserve relating to that asset are transferred to retained earnings. Financial Instruments Initial recognition and measurement Financial assets and financial liabilities are recognised when the entity becomes a party to the contractual provisions to the instrument. For financial assets, this is equivalent to the date that the company commits itself to either purchase or sell the asset (i.e. trade date accounting is adopted). Financial instruments are initially measured at fair value plus transactions costs except where the instrument is classified ‘at fair value through profit or loss’ in which case transaction costs are expensed to profit or loss immediately. Classification and subsequent measurement Financial instruments are subsequently measured at either fair value, amortised cost using the effective interest rate method or cost. Fair value represents the amount for which an asset could be exchanged or a liability settled, between knowledgeable, willing parties. Where available, quoted prices in an active market are used to determine fair value. In other circumstances, valuation techniques are adopted. Amortised cost is calculated as the amount at which the financial asset or financial liability is measured at initial recognition less principal repayments and any reduction for impairment, and adjusted for any cumulative amortisation of the difference between that initial amount and the maturity amount calculated using the effective interest method. The effective interest method is used to allocate interest income or interest expense over the relevant period and is equivalent to the rate that exactly discounts estimated future cash payments or receipts (including fees, transaction costs and other premiums or discounts) through the expected life (or when this cannot be reliably predicted, the contractual term) of the financial instrument to the net carrying amount of the financial asset or financial liability. Revisions to expected future net cash flows will necessitate an adjustment to the carrying value with a consequential recognition of an income or expense item in profit or loss. Fair value is determined based on current bid prices for all quoted investments. Valuation techniques are applied to determine the fair value for all unlisted securities, including recent arm’s length transactions, reference to similar instruments and option pricing models. (i) Financial assets at fair value through profit or loss Financial assets are classified at ‘fair value through profit or loss’ when they are held for trading for the purpose of short-term profit taking, or where they are derivatives not held for hedging purposes, or when they are designated as such to avoid an accounting mismatch or to enable performance evaluation where a group of financial assets is managed by key management personnel on a fair value basis in accordance with a documented risk management or investment strategy. Such assets are subsequently measured at fair value with changes in carrying value being included in profit or loss. (ii) Loans and receivables Loans and receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market and are subsequently measured at amortised cost. Gains or loses are recognised in profit or loss through the amortisation process and when the financial asset is derecognised. (iii) Held-to-maturity investments Held-to-maturity investments are non-derivative financial assets that have fixed maturities and fixed or determinable payments, and it is the entity’s intention to hold these investments to maturity. They are subsequently measured at amortised cost. Gains or losses are recognised in profit or loss through the amortisation process and when the financial asset is derecognised.


(iv) Available-for-sale financial assets Available-for-sale financial assets are non-derivative financial assets that are either not capable of being classified into other categories of financial assets due to their nature, or they are designated as such by management. They comprise investments in the equity of other entities where there is neither a fixed maturity nor fixed or determinable payments. They are subsequently measured at fair value with any remeasurements other than impairment losses and foreign exchange gains and losses recognised in other comprehensive income. When the financial asset is derecognised, the cumulative gain or loss pertaining to that asset previously recognised in other comprehensive income is reclassified into profit or loss. Available-for-sale financial assets are classified as non-current assets when they are expected to be sold within 12 months after the end of the reporting period. All other available-for-sale financial assets are classified as current assets. (v) Financial liabilities Non-derivative financial liabilities (excluding financial guarantees) are subsequently measured at amortised cost. Gains or losses are recognised in profit or loss through the amortisation process and when the financial liability is derecognised. Impairment At the end of each reporting period, the company assesses whether there is objective evidence that a financial asset has been impaired. A financial asset or a group of financial assets is deemed to be impaired if, and only if, there is objective evidence of impairment as a result of one or more events (a “loss event”) having occurred, which has an impact on the estimated future cash flows of the financial asset(s). In the case of available-for-sale financial assets, a significant or prolonged decline in the market value of the instrument is considered a loss event. Impairment losses are recognised in profit or loss immediately. Also, any cumulative decline in fair value previously recognised in other comprehensive income is reclassified to profit or loss at this point. Derecognition Financial assets are derecognised where the contractual rights to receipt of cash flows expires or the asset is transferred to another party whereby the entity no longer has any significant continuing involvement in the risks and benefits associated with the asset. Financial liabilities are derecognised where the related obligations are either discharged, cancelled or expired. The difference between the carrying value of the financial liability, which is extinguished or transferred to another party and the fair value of consideration paid, including the transfer of non-cash assets or liabilities assumed, is recognised in profit or loss. Impairment of Assets At the end of each reporting period, the entity reviews the carrying values of its tangible and intangible assets to determine whether there is any indication that those assets have been impaired. If such an indication exists, the recoverable amount of the asset, being the higher of the asset’s fair value less costs to sell and value in use, is compared to the asset’s carrying value. Any excess of the asset’s carrying value over its recoverable amount is recognised in profit or loss. Where the future economic benefits of the asset are not primarily dependent upon the asset’s ability to generate net cash inflows and when the entity would, if deprived of the asset, replace its remaining future economic benefits, value in use is determined as the depreciated replacement cost of an asset. Where it is not possible to estimate the recoverable amount of an assets class, the entity estimates the recoverable amount of the cash-generating unit to which the class of assets belong. Where an impairment loss on a revalued asset is identified, this is recognised against the revaluation surplus in respect of the same class of asset to the extent that the impairment loss does not exceed the amount in the revaluation surplus for that class of asset. Employee Benefits Provision is made for the company’s liability for employee benefits arising from services rendered by employees to the end of the reporting period. Employee benefits that are expected to be settled within one year have been measured at the amounts expected to be paid when the liability is settled. Employee benefits payable later than one year have been measured at the present value of the estimated future cash outflows to be made for those benefits. In determining the liability, consideration is given to employee wage increases and the probability that the employee may not satisfy vesting requirements. Those cash outflows are discounted using market yields on national government bonds with terms to maturity that match the expected timing of cash flows. Contributions are made by the entity to an employee superannuation fund and are charged as expenses when incurred. Cash and Cash Equivalents Cash and cash equivalents include cash on hand, deposits held at-call with banks, other short-term highly liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within short-term borrowings in current liabilities on the statement of financial position. Accounts Receivable and Other Debtors Accounts receivable and other debtors include amounts due from members as well as amounts receivable from customers for goods sold in the ordinary course of business. Receivables expected to be collected within 12 months of the end of the reporting period are classified as current assets. All other receivables are classified as non-current assets. Accounts receivable are initially recognised at fair value and subsequently measured at amortised cost using the effective interest rate method, less any provision for impairment.

Goods and Services Tax (GST) Revenues, expenses and assets are recognised net of the amount of GST, except where the amount of GST incurred is not recoverable from the Australian Taxation Office (ATO). Receivables and payables are stated inclusive of the amount of GST receivable or payable. The net amount of GST recoverable from, or payable to, the ATO is included with other receivables or payables in the statement of financial position.


Cash flows are presented on a gross basis. The GST components of cash flows arising from investing or financing activities, which are recoverable from or payable to the ATO, are presented as operating cash flows included in receipts from customers or payments to suppliers. Income Tax No provision for income tax has been raised as the entity is exempt from income tax under Division 50 of the Income Tax Assessment Act 1997 based on its status as a Health Promotion Charity. Provisions Provisions are recognised when the entity has a legal or constructive obligation, as a result of past events, for which it is probable that an outflow of economic benefits will result and that outflow can be reliably measured. Provisions recognised represent the best estimate of the amounts required to settle the obligation at the end of the reporting period. Comparative Figures Where required by Accounting Standards comparative figures have been adjusted to conform with changes in presentation for the current financial year. When an entity applies an accounting policy retrospectively, makes a retrospective restatement or reclassifies items in its financial statements, a statement of financial position as at the beginning of the earliest comparative period must be disclosed. Accounts Payable and Other Payables Accounts payable and other payables represent the liability outstanding at the end of the reporting period for goods and services received by the company during the reporting period which remain unpaid. The balance is recognised as a current liability with the amounts normally paid within 30 days of recognition of the liability. Critical Accounting Estimates and Judgments The directors evaluate estimates and judgments incorporated into the financial statements based on historical knowledge and best available current information. Estimates assume a reasonable expectation of future events and are based on current trends and economic data, obtained both externally and within the company. Key Estimates Impairment The freehold land and buildings were independently valued at 30 June 2010. The valuation was based on the fair value less cost to sell. The critical assumptions adopted in determining the valuation included the location of the land and buildings, the current strong demand for land and buildings in the area and recent sales data for similar properties. The valuation resulted in a revaluation increment of $214,577 being recognised for the year ended 30 June 2010. At 30 June 2012 the directors reviewed the key assumptions made by the valuers at 30 June 2010. They have concluded that these assumptions remain materially unchanged, and are satisfied that carrying value does not exceed the recoverable amount of land and buildings at 30 June 2012. New Accounting Standards for Application in Future Periods The Australian Accounting Standards Board has issued new and amended Accounting Standards and Interpretations that have mandatory application dates for future reporting periods and which the company has decided not to early adopt. A discussion of those future requirements and their impact on the company is as follows: AASB 9: Financial Instruments [December 2010] and AASB 2010-7: Amendments to Australian Accounting Standards arising from AASB 9 [December 2010] (applicable for annual reporting periods commencing on or after 1 January 2013). These Standard are applicable retrospectively and include revised requirements for the classification and measurement of financial instruments, as well as recognition and derecognition requirements for financial instruments . The company has not yet determined any potential impact on the financial statements. The key changes made to accounting requirements include: — simplifying the classifications of financial assets into those carried at amortised cost and those carried at fair value; — simplifying the requirements for embedded derivatives; — removing the tainting rules associated with held-to-maturity assets; — removing the requirements to separate and fair value embedded derivatives for financial assets carried at amortised cost; — allowing an irrevocable election on initial recognition to present gains and losses on investments in equity instruments that are not held for trading in other comprehensive income. Dividends in respect of these investments that are a return on investment can be recognised in profit or loss and there is no impairment or recycling on disposal of the instrument; — requiring financial assets to be reclassified where there is a change in an entity’s business model as they are initially classified based on (a) the objective of the entity’s business model for managing the financial assets; and (b) the characteristics of the contractual cash flows; and — requiring an entity that chooses to measure a financial liability at fair value to present the portion of the change in its fair value due to changes in the entity’s own credit risk in the other comprehensive income, except when that would create an accounting mismatch. If such a mismatch would be created or enlarged, the entity is required to present all changes in fair value (including the effects of changes in the credit risk of the liability) in profit or loss. AASB 1053: Application of Tiers of Australian Accounting Standards and AASB 2010–2: Amendments to Australian Accounting Standards arising from Reduced Disclosure Requirements [AASB 1, 2, 3, 5, 7, 8, 101, 102, 107, 108, 110, 111, 112, 116, 117, 119, 121, 123, 124, 127, 128, 131, 133, 134, 136, 137, 138, 140, 141, 1050 & 1052 and Interpretations 2, 4, 5, 15, 17, 127, 129 & 1052] (applicable for annual reporting periods commencing on or after 1 July 2013). AASB 1053 establishes a revised differential financial reporting framework consisting of two tiers of financial reporting requirements for those entities preparing general purpose financial statements: — Tier 1: Australian Accounting Standards; and — Tier 2: Australian Accounting Standards – Reduced Disclosure Requirements. Tier 2 of the framework comprises the recognition, measurement and presentation requirements of Tier 1, but contains significantly fewer disclosure requirements.


Since the company is a not-for-profit private sector entity, it qualifies for the reduced disclosure requirements for Tier 2 entities. It is anticipated that the company will take advantage of Tier 2 reporting at a later date. AASB 2010–8: Amendments to Australian Accounting Standards – Deferred Tax: Recovery of Underlying Assets [AASB 112] (applies to periods beginning on or after 1 January 2012). This Standard makes amendments to AASB 112: Income Taxes and incorporates Interpretation 121: Income Taxes - Recovery of Revalued Non-Depreciable Assets into AASB 112. Under the current AASB 112, the measurement of deferred tax liabilities and deferred tax assets depends on whether an entity expects to recover an asset by using it or by selling it. The amendments introduce a presumption that an investment property is recovered entirely through sale. This presumption is rebutted if the investment property is held within a business model whose objective is to consume substantially all of the economic benefits embodied in the investment property over time, rather than through sale. The amendments are not expected to impact the company. AASB 10: Consolidated Financial Statements, AASB 11: Joint Arrangements, AASB 12: Disclosure of Interests in Other Entities, AASB 127: Separate Financial Statements (August 2011), AASB 128: Investments in Associates and Joint Ventures (August 2011) and AASB 2011–7: Amendments to Australian Accounting Standards arising from the Consolidation and Joint Arrangements Standards [AASB 1, 2, 3, 5, 7, 9, 2009–11, 101, 107, 112, 118, 121, 124, 132, 133, 136, 138, 139, 1023 &1038 and Interpretations 5, 9, 16 & 17] (applicable for annual reporting periods commencing on or after 1 January 2013). AASB 10 replaces parts of AASB 127 [March 2008, as amended] and Interpretation 112: Consolidation – Special Purpose Entities. AASB 10 provides a revised definition of control and additional application guidance so that a single control model will apply to all investees. The company has not yet been able to reasonably estimate the impact of this Standard on its financial statements. AASB 11 replaces AASB 131: Interests in Joint Ventures (July 2004, as amended). AASB 11 requires joint arrangements to be classified as either “joint operations” (where the parties that have joint control of the arrangement have rights to the assets and obligations for the liabilities) or “joint ventures” (where the parties that have joint control of the arrangement have rights to the net assets of the arrangement). Joint ventures are required to adopt the equity method of accounting (proportionate consolidation is no longer allowed). AASB 12 contains the disclosure requirements applicable to entities that hold an interest in a subsidiary, joint venture, joint operation or associate. AASB 12 also introduces the concept of a “structured entity”, replacing the “special purpose entity” concept currently used in Interpretation 112, and requires specific disclosures in respect of any investments in unconsolidated structured entities. This Standard will affect disclosures only and is not expected to significantly impact the company. To facilitate the application of AASBs 10, 11 and 12, revised versions of AASB 127 and AASB 128 have also been issued. These Standards are not expected to significantly impact the company. AASB 13: Fair Value Measurement and AASB 2011–8: Amendments to Australian Accounting Standards arising from AASB 13 (applicable for annual reporting periods commencing on or after 1 January 2013). AASB 13 defines fair value, sets out in a single Standard a framework for measuring fair value, and requires disclosures about fair value measurement. AASB 13 requires: — inputs to all fair value measurements to be categorised in accordance with a fair value hierarchy; and — enhanced disclosures regarding all assets and liabilities (including, but not limited to, financial assets and financial liabilities) measured at fair value. This Standard is not expected to impact the company. AASB 2011–9: Amendments to Australian Accounting Standards – Presentation of Items of Other Comprehensive Income (applicable for annual reporting periods commencing on or after 1 July 2012). The main change arising from this Standard is the requirement for entities to group items presented in other comprehensive income (OCI) on the basis of whether they are potentially reclassifiable to profit or loss subsequently. This Standard affects presentation only and is therefore not expected to significantly impact the company. AASB 119: Employee Benefits [September 2011] and AASB 2011–10: Amendments to Australian Accounting Standards arising from AASB 119 (applicable for annual reporting periods commencing on or after 1 January 2013) These Standards introduce a number of changes to accounting and presentation of defined benefit plans. The company does not have any defined benefit plans and so is not impacted by the amendment. AASB 119 [September 2011] also includes changes to: (a) require only those benefits that are expected to be settled wholly before 12 months after the end of the annual reporting period in which the employees render the related service to be classified as short-term employee benefits. All other employee benefits are to be classified as either other long-term employee benefits, post-employment benefits or termination benefits, as appropriate; and (b) the accounting for termination benefits that require an entity to recognise an obligation for such benefits at the earlier of: (i) where for an offer that may be withdrawn – when the employee accepts;


(ii) where for an offer that cannot be withdrawn – when the offer is communicated to affected employees; and (iii) where the termination is associated with a restructuring of activities under AASB 137 and if earlier than the first two conditions – when the related restructuring costs are recognised. The company has not yet been able to reasonably estimate the impact of these changes to AASB 119. 2. Revenue 2012 2011 $ $Sale of goods 451,422 57,970 Advertising income 79,887 80,430 Grants & support 535,566 615,965Royalties 110,275 54,417 Interest received 198,810 178,540 Rendering of services 1,847,899 1,817,121 Rental income & outgoings 11,367 41,807 Recovery of Expenses 56,524 - Other revenue 9,199 7,927 Total revenue 3,300,949 2,854,177 3. Profit for the Year Expenses: Cost of sales 144,504 18,062 Depreciation of non-current assets Depreciation - plant & equipment 49,472 42,331 Depreciation - property improvements 426 383 Depreciation - buildings 24,625 24,625 Total depreciation 74,523 67,339 Loss on disposal of non-current assets 481 3,271 Remuneration of auditor Auditing the accounts 11,150 14,000 Other services 6,350 5,460 17,500 19,460 4. Cash and Cash Equivalents Cash on hand 1,976 1,976 Term deposits 3,063,191 2,786,736 Cash at bank - Federal operating account 238,001 289,855 Cash at banks, building societies, credit unions 1,040,295 614,566 Total cash and cash equivalents as stated in the statement of financial position 4,343,463 3,693,133 Total cash and cash equivalents as stated in the cash flow statement 4,343,463 3,693,133 5. Accounts Receivable and Other Debtors Current Trade receivables 172,313 289,415 172,313 289,415 Other receivables 730 159 Total current trade and other receivables 173,043 289,574

(i) Credit Risk — Trade and Other Receivables The company does not have any material credit risk exposure to any single receivable or group of receivables. The following table details the company’s trade and other receivables exposed to credit risk (prior to collateral and other credit enhancements) with ageing analysis and impairment provided for thereon. Amounts are considered as “past due” when the debt has not been settled within the terms and conditions agreed between the company and the customer or counter party to the transaction. Receivables that are past due are assessed for impairment by ascertaining solvency of the debtors and are provided for where there are specific circumstances indicating that the debt may not be fully repaid to the company. The balances of receivables that remain within initial trade terms (as detailed in the table) are considered to be of high credit quality. Past due Past due but not impaired Gross and (days overdue) With initial amount impaired <30 31-60 61-90 >90 trade terms $ $ $ $ $ $ $2011 Trade and term receivables 289,416 - 272,560 2,200 3,300 11,356 - Other receivables 159 - - - - - 159 Total 289,575 - 272,560 2,200 3,300 11,356 159 2012 Trade and term receivables 172,313 - 16,902 12,375 - - 143,036 Other receivables 730 - - - - - 730 Total 173,043 - 16,902 12,375 - - 143,766


6. Inventories on Hand 2012 2011 $ $Current At cost: Stock on hand 6,051 440 7. Other Current Assets Current Accrued income 61,800 80,037 Prepayments 171,907 74,563 233,707 154,600 8. Property, Plant and Equipment Land and Buildings Freehold land at fair value: 65 - 69 Oxford Street Collingwood - Independent valuation in 2010 462,375 462,375 Buildings at cost: Suites 3 & 4, 65 - 69 Oxford Street Collingwood - at cost 985,000 985,000 Less: accumulated depreciation (169,189) (144,564) 815,811 840,436 Property improvements - at cost 17,087 17,087 Less: accumulated depreciation (2,092) (1,666) 14,995 15,421 Total land and buildings 1,293,181 1,318,232 Plant and equipment Office furniture & equipment - at cost 239,157 203,698 Less: accumulated depreciation (161,734) (120,179) 77,423 83,519 Total plant and equipment 77,423 83,519 Total property, plant and equipment 1,370,604 1,401,751 Movements in Carrying Amounts Movements in carrying amount for each class of property, plant and equipment between the beginning and the end of the current financial year. Plant Equipment & Property Land Buildings Improvements Total 2011 $ $ $ $Balance at the beginning of the year 462,375 865,061 90,734 1,418,170Additions - - 54,191 54,191Disposals - - (3,271) (3,271) Revaluation increment - - - -Depreciation expense - (24,625) (42,714) (67,339) Carrying amount at the end of the year 462,375 840,436 98,940 1,401,751 Plant Equipment & Property Land Buildings Improvements Total2012 $ $ $ $Balance at the beginning of the year 462,375 840,436 98,940 1,401,751 Additions - - 44,587 44,587 Disposals - - (1,211) (1,211)Revaluation increment - - - - Depreciation expense - (24,625) (49,898) (74,523)Carrying amount at the end of the year 462,375 815,811 92,418 1,370,604 Asset revaluations The freehold land and buildings were independently valued at 30 June 2010. The valuation was based on the fair value less cost to sell. The critical assumptions adopted in determining the valuation included the location of the land and buildings, the current strong demand for land and buildings in the area and recent sales data for similar properties. The valuation resulted in a revaluation increment of $214,577 being recognised in the Revaluation Surplus for the year ended 30 June 2010. At 30 June 2012 the directors reviewed the key assumptions made by the valuers at 30 June 2010. They have concluded that these assumptions remain materially unchanged, and are satisfied that carrying value does not exceed the recoverable amount of land and buildings at 30 June 2012.


9. Accounts Payable and Other Payables 2012 2011 $ $Current Income in advance 1,316,674 1,105,197 Other payables & accruals 117,052 129,903 Awards in trust 146,761 217,681 GST payable 94,260 83,650 1,674,747 1,536,431 Financial liabilities at amortised cost classified as trade and other payables Trade and other payables - Total current 1,674,747 1,536,431 - Total non-current - - 1,674,747 1,536,431 Less income in advance (1,316,674) (1,105,197) Financial liabilities as trade and other payables 358,073 431,234 10. Provisions for Employee Benefits Current Provision for employee benefits 128,470 116,760

Non-Current Provision for employee benefits - - Aggregate employee benefit liability 128,470 116,760 Provision for Long-term Employee Benefits A provision has been recognised for employee entitlements relating to long service leave. In calculating the present value of future cash flows in respect of long service leave, the probability of long service leave being taken is based on historical data. The measurement and recognition criteria relating to employee benefits have been included in Note 1 to these financial statements. 11. Capital and Leasing Commitments Operating Lease Commitments Non-cancellable operating leases contracted for but not recognised in the financial statements. Payable - minimum lease payments — not later than 12 months 6,264 7,286 — Later than 12 months but not later than 5 years 10,440 19,430 — Greater than 5 years - - 16,704 26,717 The photocopier lease commitment is a non-cancellable operating lease contracted for but not recognised in the financial statements with a five-year term 12. Contingent Liabilities and Assets There are no material contingent liabilities and assets which are required to be disclosed in the financial statements at reporting date. 13. Events After the Reporting Period There are no significant events after the reporting date which are required to be disclosed in the financial statements. 14. Related Party Transactions a. Key Management Personnel Any person(s) having authority and responsibility for planning, directing and controlling the activities of the company, directly or indirectly, including any director (whether executive or otherwise) is considered key management personnel. — short-term benefits 220,085 225,987 — post-employment benefits - - — other long-term benefits - - 220,085 225,987 b. Other Related Parties Transactions between related parties are on normal commercial terms and conditions no more favourable than those available to other persons unless otherwise stated. There were no transactions with related parties during the year. 15. Cash Flow Information Reconciliation of Cashflow from Operations with Profit after Income Tax Profit after income tax 437,344 178,553

Non-cash flows Loss on sale of non-current assets 481 3,271 Depreciation 74,523 67,339 Changes in assets and liabilities (Increase) Decrease in inventories (5,611) 4,435 (Increase) Decrease in trade and other receivables 116,531 (107,261) (Increase) Decrease in other current assets (79,107) 4,461 Increase (Decrease) in trade and other payables 138,316 438,212 Increase (Decrease) in employee provisions 11,710 31,671 694,187 620,681


16. Financial Risk Management The company’s financial instruments consist mainly of deposits with banks, local money market instruments, short-term and long-term investments, accounts receivable and payable and leases. The carrying amounts for each category of financial instruments, measured in accordance with AASB 139 as detailed in the accounting policies to these financial statements, are as follows: Note 2012 2011 $ $ Financial Assets Cash and cash equivalent 4 4,343,463 3,693,133 Trade and other receivables 5 173,043 289,574 4,516,506 3,982,707 Financial Liabilities Trade and other payables 9 358,073 431,234 358,073 431,234 (i) Financial Risk Management Policies The finance committee consists of senior committee members, and the committee’s overall risk management strategy is to assist the company in meeting its financial targets whilst minimising potential adverse effects on financial performance. Risk management policies are approved and reviewed by the finance committee on a regular basis. These include credit risk policies and future cash flow requirements. (ii) Specific Financial Risk Exposures and Management The main risks the company is exposed to through its financial instruments are credit risk, liquidity risk and market risk relating to interest rate risk and equity price risk. There have been no substantive changes in the types of risks the company is exposed to, how these risks arise, or the board’s objectives, policies and processes for managing or measuring the risks from the previous period. a. Credit risk Exposure to credit risk relating to financial assets arises from the potential non-performance by counterparties of contract obligations that could lead to a financial loss for the company. Credit risk is managed through the maintenance of procedures (such procedures include the utilisation of systems for the approval, granting and removal of credit limits, regular monitoring of exposures against such limits and monitoring of the financial stability of significant customers and counter parties), ensuring to the extent possible, that customers and counter parties to transactions are of sound credit worthiness. Such monitoring is used in assessing receivables for impairment. Credit Risk Exposure The maximum exposure to credit risk by class of recognised financial assets at the end of the reporting period is equivalent to the carrying value and classification of those financial assets (net of any provisions) as presented in the statement of financial position. Trade and other receivables that are neither past due or impaired are considered to be of high credit quality. Aggregates of such amounts are as detailed at Note 5. The company has no significant concentrations of credit risk exposure to any single counterparty or group of counterparties. Details with respect to credit risk of Trade and Other Receivables are provided in Note 5. b. Liquidity risk Liquidity risk arises from the possibility that the company might encounter difficulty in settling its debts or otherwise meeting its obligations in relation to financial liabilities. The company manages this risk through the following mechanisms: preparing forward looking cash flow analysis in relation to its operational, investing and financing activities; maintaining a reputable credit profile; managing credit risk related to financial assets; only investing surplus cash with major financial institutions; and comparing the maturity profile of financial liabilities with the realisation profile of financial assets. Cash flows realised from financial assets reflect management’s expectation as to the timing of realisation. Actual timing may therefore differ from that disclosed. The timing of cash flows presented in the table to settle financial liabilities reflects the earliest contractual settlement dates. Financial liability and financial asset maturity analysis Within 1 Year Total 2012 2011 2012 2011 $ $ $ $ Financial liabilities due for payment Trade and other payables (excluding estimated 358,073 431,234 358,073 431,234 annual leave and deferred income Total expected outflows 358,073 431,234 358,073 431,234 Financial Assets — cash flows realisable Cash and cash equivalents 4,343,463 3,693,133 4,343,463 3,693,133 Trade, term and loans receivables 173,043 289,574 173,043 289,574 Total anticipated inflows 4,516,506 3,982,707 4,516,506 3,982,707 Net (outflow)/inflow on financial instruments 4,158,433 3,551,473 4,158,433 3,551,473


c. Market risk i. Interest rate risk Exposure to interest rate risk arises on financial assets and financial liabilities recognised at the end of the reporting period whereby a future change in interest rates will affect future cash flows or the fair value of fixed rate financial instruments. The company is also exposed to earnings volatility on floating rate instruments. The company did not have any loans with financial institutions during the year.

ii. Price risk Price risk relates to the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices of securities held. The company was not significantly exposed to price risk during the year. (iii) Sensitivity Analysis The following table illustrates sensitivities to the company’s exposures to changes in interest rates and equity prices. The table indicates the impact on how profit and equity values reported at the end of the reporting period would have been affected by changes in the relevant risk variable that management considers to be reasonably possible. These sensitivities assume that the movement in a particular variable is independent of other variables. Profit Equity $ $ Year ended 30 June 2011 +/-2% in interest rate +/- 68158 +/- 68158 Year ended 30 June 2012 +/-2% in interest rates +/- 80326 +/- 80326 No sensitivity analysis has been performed on foreign exchange risk as the company is not exposed to foreign currency fluctuations. (iv) Net Fair Values The fair values of financial assets and financial liabilities can be compared to their carrying values as presented in the statement of financial position. Fair values are those amounts at which an asset could be exchanged, or a liability settled, between knowledgeable, willing parties in an arm’s length transaction. Monetary financial assets and liabilities not readily traded in an organised financial market are determined by valuing them at the present value of contractual future cash flows on amounts due from customers (reduced except for credit losses) or due to suppliers. Cash flow are discounted using standard valuation techniques at the applicable market yield having regard to the timing of the cash flows. The net fair value of assets and liabilities approximates their carrying value at reporting date. 17. Capital Management Management controls the capital of the entity to ensure that adequate cash flows are generated to fund its mentoring programs and that returns from investments are maximised within tolerable risk parameters. The finance committee ensures that the overall risk management strategy is in line with this objective. The finance committee operates under policies approved by the Board of Directors. Risk management policies are approved and reviewed by the Board on a regular basis. These include credit risk policies and future cash flow requirements. The entity’s capital consists of financial liabilities, supported by financial assets. Management effectively manages the entity’s capital by assessing the entity’s financial risks and responding to changes in these risks and in the market. These responses may include the consideration of debt levels. There have been no changes to the strategy adopted by management to control the capital of the entity since the previous year. 18. Reserves Revaluation Surplus The revaluation surplus records the revaluations of non-current assets. 19. Entity Details The registered office and principal place of business is at: Suite 3, 65 Oxford Street Collingwood VIC 3066 20. Members’ Guarantee The entity is incorporated under the Corporations Act 2001 and is an entity limited by guarantee. If the entity is wound up, the constitution states that each member is required to contribute a maximum of $20 each towards meeting any outstandings and obligations of the entity. At 30 June 2012 the number of members was 3,048.


directors’ declaration The directors of the company declare that: 1. The financial statements and notes, as set out on pages 27 to 37, are in accordance with the Corporations Act 2001: (a) comply with Australian Accounting Standards; and (b) give a true and fair view of the financial position as at 30 June 2012 and of the performance for the year ended on that date of the entity. 2. In the directors’ opinion there are reasonable grounds to believe that the entity will be able to pay its debts as and when they become due and payable. This declaration is made in accordance with a resolution of the Board of Directors. Director: Director: Suzanne Kirsa Anthony Hall Dated this 7th day of September 2012 independent audit report to the members of the Society of Hospital Pharmacists of Australia Limited ABN 54 004 553 806

We have audited the accompanying financial statements of The Society Of Hospital Pharmacists Of Australia Ltd (the company), which comprises the statement of financial position as at 30 June 2012 and the income statement, statement of comprehensive income, statement of changes in equity and statement of cash flows for the year ended on that date, a summary of significant accounting policies and other explanatory notes and the directors’ declaration. the responsibility of the directors for the financial statements The directors of the company are responsible for the preparation of the financial report that gives a true and fair view in accordance with Australian Accounting Standards (including the Australian Accounting Interpretations) and the Corporations Act 2001 and for such internal control as the directors determine is necessary to enable the preparation of the financial report that is free from material misstatement, whether due to fraud or error. auditor’s responsibility

Our responsibility is to express an opinion on the financial report based on our audit. We conducted our audit in accordance with Australian Auditing Standards. Those standards require that we comply with relevant ethical requirements relating to audit engagements and plan and perform the audit to obtain reasonable assurance whether the financial report is free from material misstatement. An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial report. The procedures selected depend on the auditor’s judgment, including the assessment of the risks of material misstatement of the financial report, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity’s preparation of the financial report that gives a true and fair view in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity’s internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the directors, as well as evaluating the overall presentation of the financial report. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion. independence In conducting our audit, we have complied with the independence requirements of the Corporations Act 2001. auditor’s opinion In our opinion, the financial report of The Society of Hospital Pharmacists Of Australia Ltd Limited is in accordance with the Corporations Act 2001, including:

(i) giving a true and fair view of the company’s financial position as at 30 June 2012 and of its performance for the year ended on that date; and (ii) complying with Australian Accounting Standards and the Corporations Regulations 2001.

ANDERSON AUDITORS ROBERT F. CINCOTTA Chartered Accountants Partner Level 6, 484 St Kilda Road, Melbourne VIC 3004 Dated this 7th day of September 2012



Date post:	22-Mar-2018
Category:	Documents
Upload:	hoangkhanh
View:	218 times
Download:	4 times

annual report 2012 - shpa.org.au · PDF fileThe Society of Hospital Pharmacists of Australia...

Documents